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1. Introduction 
According to the International Diabetes Federation 285 million people at the age 
of 20 to 79 are affected by diabetes worldwide. 439 million are expected to be 
diagnosed with diabetes in the year 2030. Type 2 diabetes accounts for 90 to 
95 % of all cases of diabetes. The costs for this chronic disease amount to 
approximately US$ 376 billion worldwide [International Diabetes Federation, 
2010].  
Diabetes results in the organism’s inability to generate insulin or to the 
insufficient use of insulin. The consequence is an increased blood glucose level. 
Diabetes and its serious, possible consequences have a significant impact on 
the quality of life, social impact and economic costs Murray et al., 2011. 
Morbidity and mortality rates are of higher and life expectancy of lower 
occurrence in diabetes type 2 patients than in the population without the 
disease. Coronary disease is one of the major secondary diseases, which may 
be evoked by oxidative stress. Oxidative stress itself is generated in the 
organism due to the imbalance of the protective antioxidants and the free 
radical production, which causes oxidative damage. Oxidative stress and 
consequently oxidative damage are evidentially higher in diabetes patients 
Hanachi et al., 2009. However, chronic oxidative stress causes damage to 
biological macromolecules, for example DNA, proteins, carbohydrates, lipids 
and interference in cellular homeostasis. It has to be said that the detailed 
mechanism of oxidative stress causing diabetic complications still has not been 
completely understood Kowluru and Chan, 2007. Therefore it is of major 
importance to focus on diabetes prevention in the first priority. Modifiable 
factors, such as lifestyle and diet habits are presently underestimated and must 
be one focus in future.  
 
The intervention study “Diaplant” has been realized at the Department of 
Nutritional Sciences in Vienna, Emerging Field Oxidative Stress and DNA 
Stability, in order to evaluate whether a daily intake of a certain amount of 
vegetables and plant oil over a period of 8 weeks has positive effects on risk 
parameters in type 2 diabetes subjects. Desired effects among others would be 
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an improved glycemic control due to higher insulin sensitivity, reduced 
cholesterol and triglyceride levels and an improved antioxidative capacity, which 
tends to be lower in diabetes patients.  
This thesis is focusing on the impact of a dietary intervention in subjects with 
type 2 diabetes on antioxidative capacity measured with the FRAP- (ferric 
reducing ability of plasma) and the ORAC- (oxygen radical absorbance 
capacity) assay and furthermore on malondialdehyde (MDA), which is a marker 
for lipid peroxidation.  
 
2. Literature overview 
2.1. Diabetes mellitus 
2.1.1 Pathogenesis and Classification of Diabetes mellitus 
Diabetes is a heterogeneous disorder characterized by hyperglycemia resulting 
from insulin resistance and/or from ß-cell defects Lodovici et al., 2009. Chronic 
increased glucose levels cause long-term damage, dysfunction and impairment 
of various organs such as eyes, kidneys, heart, nerves and blood vessels. 
Various harmful processes play a decisive role in the development of diabetes. 
Type 1 diabetes mellitus is characterized by destruction of ß-cells in the 
pancreas due to autoimmune disorder leading to an ongoing insulin deficiency 
and further causing insulin resistance. In type 2 diabetes both the defects in 
insulin secretion and insulin resistance occur in the same subject and it is 
therefore uncertain what exactly causes hyperglycemia. Symptoms of diabetes 
can be polyuria, weight loss, polydipsia and blurred vision. Poorly controlled, 
long-lasting diabetes causes complications like retinopathy with a possible loss 
of vision, peripheral neuropathy posing a risk of foot ulcers or amputations, 
retinopathy causing a renal malfunction and not least, autonomic neuropathy 
generating gastrointestinal, cardiovascular and genitourinary diseases 
American Diabetes Association, 2009. 
 
Diabetes mellitus is classified into 4 groups (according to the American 
Diabetes Association): 
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1. Diabetes mellitus Type 1 
5-10% out of all diabetes cases belong to Type 1. As mainly younger people 
and children are affected by type 1 diabetes, it is also called juvenile-onset 
diabetes based on a cellular-mediated autoimmune destruction of the ß-cells in 
the pancreas, usually leading to absolute insulin deficiency. About 95% develop 
it before the age of 25 with a rather higher incidence in Kaukasian people. 
Furthermore, patients with type 1 diabetes have often a gluten enteropathy 
(celiac disease) or other endocrine disorders. The autoimmune destruction of ß-
cells is caused by genetic predispositions and might be associated with 
environmental issues. 
 
2. Diabetes mellitus Type 2 
Type 2 diabetes is characterized by insulin resistance with a relative insulin 
deficiency. 90-95% of all diabetes cases belong to this type. Most of the people 
who have diabetes type 2 are also overweight or obese which increases the 
degree of insulin resistance. Factors like higher age, obesity, lack of physical 
activity and lifestyle influence the development of the disease.  Type 2 diabetes 
is also associated with genetic predisposition (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Stages and risk factors in development of type 2 diabetes Steyn et al., 2004 
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3. Specific diabetes-types 
These types are caused by diseases of the exocrine pancreas (pancreatitis, 
trauma, cystic fibrosis), endocrine organs (Cushing-Syndrom, Acromegaly), 
medical-chemical factors (Glucocorticoide, -Interferone), genetic defects in the 
insulin secretion and insulin effects, other genetic syndromes (Down, Klinefelter, 
Turner syndrome) or infections and rare forms of auto-immune mediated 
diabetes (“Stiff-man”-syndrom). 
 
4. Gestational diabetes 
Gestational diabetes is diagnosed during/after pregnancy and based on an 
impaired glucose-tolerance. 1-5% of all pregnant women are affected and 
gestational diabetes constitutes one of the most common complications during 
pregnancy.  
 
 
2.1.2 Diagnosis of diabetes mellitus 
 
Criteria for the diagnosis of diabetes mellitus (American Diabetes 
Association): 
 
 HbA1C  6.5 %: The test should be performed in a laboratory using a method 
that is NGSP (National Glycohemoglobin Standardization Program) certified 
and standardized to the DCCT (Diabetes Control and Complications Trial) 
assay (in US).  
OR 
 FPG 126 mg/dl (7.0 mmol/l): Fasting is defined as no caloric intake for at 
least 12 h.  
OR 
 
 2-h plasma glucose  200 mg/dl (11.1 mmol/l) during an OGTT: The test 
should be performed as described by the World Health Organization. 
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OR 
 
 In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, 
a random plasma glucose 200  mg/dl (11.1 mmol/l). 
 
 
HbA1c or glycated hemoglobin is an important diagnostic or screening tool 
describing the blood glucose levels for the past 8 weeks. The normoglycemic 
levels for HbA1c are between 4-6%;  6.5 % is considered as hyperglycemic 
Kay-Tee Khaw et al., 2001.  
 
2.1.3 Complications and delayed consequences  
As diabetes is a chronic, life-long disease, it is very important to ensure a good 
metabolic control of the disease. An early metabolic adjustment can delay 
diabetic long-term complications. Metabolic imbalances, like hyperglycemia or 
hypoglycemia occur often in diabetic people and are responsible for 
complications Elmadfa and Leitzmann, 2004. In general, diabetics have a 
higher total mortality than non-diabetics mainly due to secondary diseases. 
Cardiovascular diseases are the major cause of death both in type 1 and type 2 
diabetes. The two most common acute complications for diabetes patients are 
the diabetic coma and hypoglycemia or the so-called diabetic shock. The 
diabetes associated-complications are structured into macro- and microvascular 
complications. Macrovascular complications affect the cardiovascular system 
whereas the eyes, kidneys and the nervous system are affected by 
microvascular complications. High fasting blood glucose levels and high blood 
pressure are the main risk factors for microvascular diseases as well as the 
cholesterol level for retinopathy. The main risk factor for macrovascular 
diseases is high blood pressure and the blood cholesterol for coronary heart 
diseases. The macrovascular complications in diabetics correspond to the 
disease pattern of arteriosclerosis and its manifestations Österreichischer 
Diabetesbericht 2004. 
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 Cardiovascular disease:  
Mainly the heart and blood vessels are affected. The consequences are fatal 
complications such as coronary heart disease (causing heart attack) and stroke.  
 
 Kidney disease (diabetic nephropathy):  
At worse, it can lead to total kidney failure associated with dialysis or kidney 
transplantation.  
 
 Nerve disease (diabetic neuropathy): 
This disease can cause ulceration and amputation of the toes, feet and lower 
limbs. Another major risk is the loss of feeling in limbs and therefore increase in 
foot injuries, which are not noticed by patients. This fact leads to a higher rate of 
infections and amputations.  
 
 Eye disease (diabetic retinopathy): 
The retina of the eye is affected which can lead to a vision loss (in the worst 
case). 
 
2.1.4 Therapy  
In order to optimize the blood glucose levels and to minimize delayed 
complications, the following points are needed to achieve that target: 
 
 Physical Activity:  
A moderate physical activity of at least 30 minutes per day (e.g. walking, 
cycling, swimming, dancing) should be performed preferably on most days of 
the week. 
 
 Body weight: 
Weight loss decreases insulin resistance, improves blood glucose and high lipid 
levels in the short term and further decreases blood pressure. It is desirable and 
important to reach and maintain a normal body weight.  
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 Healthy diet: 
Avoid a diet rich in sugars and saturated fatty acids and reduce alcohol 
consumption. 
 
 Avoid tobacco: 
Tobacco consumption increases the risk for complications in people with 
diabetes. 
 
 Monitoring of complications: 
Monitoring of complications and regular check-ups are recommended in a good 
diabetes care. Furthermore the risks for cardiovascular and kidney diseases 
should be assessed. Regular foot and eye checks, blood pressure and glucose 
control should be done.  
 
A therapy consisting of lifestyle changes and in an advanced disease state, 
medication with oral antidiabetics and/or insulin is necessary International 
Diabetes Federation 2011. 
 
Type 2 diabetes mellitus is characterized by the chronic loss in the efficiency in 
insulin producing cells. Therefore insulin injection is needed.  
 
A therapy consists of insulinotropic and non-insulinotropic mediaction as well as 
insulin.  
 
Medication for type 2 diabetes (Hien and Böhm, 2007): 
 Insulinotropic medication (Sulphonylureas, Glinide/sulphonylureas-analog) 
 Insulin-sensitizers (non-insulinotropic medication): Metformin 
 -Glucosidase-Inhibitors (non-insulinotropic medication) 
 Insulin 
Insulin constitutes an immediate component of a mono and combination therapy 
in type 2 diabetes.  
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2.1.5 Epidemiology of diabetes mellitus 
The prevalence of diabetes mellitus is rising worldwide, especially in developing 
countries. India and China will be having the highest numbers of diabetics, 
especially due to higher incidence rates in the next decades Wild et al., 2004. 
In Europe and the United States, the trend is attributed to an increase in life 
expectancy and the aging population. Nowadays diagnostic criteria have been 
further advanced, therefore diagnosis is earlier. Prediabetic has great impact on 
cardiovascular morbidity and mortality. For elderly aged  70 years, the 
prevalence is almost twofold higher in comparison to the last decade of life 
Bruno et al., 1999.  
According to a recent study published by DANAEI et al. (2011) 347 million 
people suffered from diabetes worldwide in 2008. 3.4 million died in 2004 due to 
hyperglycemic long-term complications. It is assumed that the number of 
diabetics will double between the years 2005 and 2030 WHO, 2011. 
In the year 2010, 285 million people were diagnosed with diabetes mellitus 
worldwide and in 2030 438 million cases are expected. International Diabetes 
Federation, 2011.  
In Austria 600 000 people are estimated to suffer from DM, whereas only  
420 000 are diagnosed and receive medical treatment. 180 000 people who are 
affected do not even know about their disease ÖDG, 2010. 
 
2.1.6 Diabetes and Costs 
Due to the constantly increasing diabetes prevalence and the tight resources, 
the economical impact of diabetes is being more and more crucial. According to 
the CODE-2-study (“The Cost of Diabetes in Europe – Type II study), which is 
based on the 8 European countries, the direct medical costs of type 2 diabetes 
amounts to 29 billion Euro. This constitutes 5% of the total health expenditures. 
In-patients hospitalization accounted for 55%, followed by 27% for medication, 
whereas only 7% of the costs were spent for specific diabetic medication 
(insulin, oral antidiabetic) and 18% for outpatient care Rieder et al., 2004. 
The global health expenditure on diabetes is estimated to amount to USD 376 
billion, which is 12 % of the total health expenditure in 2010. About 80 % of the 
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countries worldwide spent 5-13 % of their national health expenditures for the 
disease. The United States of America alone spent approximately half of the 
global costs. Less than 10 % was spent by the low- and middle-income 
countries where 70% of people with diabetes lived in 2010. India has the largest 
population of diabetics and accounts for less than 1 % of the world’s total 
expenditures Zhang et al., 2010 
 
2.2. Free radical metabolism and Oxidative stress 
 
2.2.1 Free radicals 
A free radical is a molecule with one or more unpaired electrons in its orbit and 
is able to exist independently. It is extremely reactive due to its instability and 
seeks for an electron from other molecules to ensure chemical stability. 
Consequently, the new molecule becomes a free radical itself, which leads to a 
chain reaction interfering with the integrity of a cell Clarkson and Thomson, 
2000. Free radicals are involved in a high number of subsequent reactions, 
which leads to the formation of other reactive metabolites. Mostly diverted from 
oxygen (reactive oxygen species – ROS) and nitrogen (reactive nitrogen 
species – RNS), they are produced in our body by several endogenous 
systems, under various physiochemical exposure or pathophysiological states. 
ROS include superoxide O2-, hydroxyl radical OH.-, hydrogen peroxide H2O2, 
peroxyl radical ROO-, organic hydroperoxide ROOH, singlet oxygen 1O2 and 
ozone O3. Reactive nitrogen species include nitric oxide (NO-), peroxynitrite 
ONOO-, peroxynitrous acid ONOOH and nitrogen dioxide NO2. Those free 
radicals can unfavorably change lipid structures, proteins and DNA and are 
further responsible for aging and various human diseases. Impairments of DNA 
can lead to mutagenesis and carcinogenesis Devasagayam et al., 2004. 
Further ROS can also be produced by sources other than mitochondrial 
electron transport chain as there are cytochrome P450 and the NADPH 
oxidase. Oxygenated free radicals are able to change vascular function and 
disrupt cellular homeostasis, particularly by blocking synthesis and action of 
NO- and further by activating NFkB in endothelial cells Wautier et al., 1994. 
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Moreover, nitrite oxide has been associated with autoimmune pancreatic ß-cell 
impairment in insulin-dependent type 1 diabetes Corbett and McDaniel, 1992.  
On the other hand, many ROS play important roles in physiological processes 
and systems, as there are microbiological destruction, blood pressure control, 
endothelial capacity, cell signaling, cell division, apoptosis and gene 
transcription Suzuki et al., 1997. Therefore strategies are necessary to reduce 
the damaging interplay between ROS and precious substrates like protein thiol 
groups, DNA bases and polyunsaturated fatty acids (PUFA) Beckman and 
Ames, 1998.  
 
2.2.2 Antioxidants  
To prevent oxidant-induced damage, antioxidants are of great importance. An 
antioxidant is defined simply as anything that obviates oxidation of an 
accessible base. Antioxidant systems are indeed elaborated and endeavoured 
to reduce the ROS load, to convert them to lower reactive products Sies, 
1997. The human antioxidant protection system is effective but of course not 
impeccable. Consequently, oxidative damage arises in key biological systems 
and it can accumulate over the years, which leads to aging and age-related 
diseases. This does not constitute a failure of evolution but it is rather a 
fundamental evolutionary principle Ames et al., 1993. Cells have a protection 
by a complex interconnected system of antioxidants. The enzymatic and non-
enzymatic antioxidants are obtained in both the intracellular and the 
extracellular surroundings and are in charge of eliminating various reactive 
oxygen species. Table 1 and 2 give an overview of the main functions of 
enzymatic and non-enzymatic antioxidants Benzie, 2002. 
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Tab. 1: Important enzymatic antioxidants Benzie, 2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 2: List of selected dietary antioxidants Benzie, 2002 
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2.2.3 Oxidative stress  
Oxidative stress is an undesirable state based on an imbalance between 
oxidants and antioxidants on behalf of the oxidants SIES, 1996 (Fig. 2). The 
dimension of oxidative stress depends on the capability of the organism to 
inactivate ROS, which constitutes the antioxidant defense SEN, 2001. 
Important affecting factors for oxidative stress can be adverse physiochemical, 
environmental or pathological conditions that involve e.g. atmospheric toxins, 
ultraviolet rays, cigarette smoke, radiation, toxic chemicals, overnutrition and 
increased glycation end products in diabetes mellitus. Consequently, an 
imbalance in favor of pro-oxidants leads to oxidative stress which is discussed 
to be associated with various human diseases (more than 100) and with aging 
Devasagayam et al., 2004.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Oxidative stress due to imbalance of ROS/RNS and antioxidants Elmadfa und 
Leitzmann, 2004 
 
Antioxidants 
ROS/RNS 
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2.3. Oxidative stress in diabetes mellitus 
Oxidative stress has been said to be involved in the onset and the progression 
of diabetes and its complications. The oxidative milieu and its consequences 
induce insulin resistance, ß-cell dysfunction, mitochondrial dysfunction and 
disordered glucose tolerance that is consequently causing the diabetic state. 
Oxidative stress initializes a number of stress pathways including the family of 
serine/threonine kinases, which might have negative influence on insulin 
signaling. Far more experimental studies are required to figure out the 
mechanisms, which are responsible for insulin resistance in diabetes. Through 
measures such as the control of hyperglycemia and adequate caloric intake 
oxidative stress is being able to be kept low Rains and Jain, 2011. 
Additionally, oxidative stress has also been linked to long-term diabetic 
complications, including microvascular and macrovascular dysfunction. It is also 
involved in promoting the development of nephropathy, neuropathy, myocardial 
injury and retinopathy Kowluru and Chan, 2007. Furthermore, the reaction of 
glucose with plasma proteins lead to the production of advanced glycation end 
products which is triggering the formation of ROS. These ROS initiate a chain 
reaction causing higher risk markers for inflammation and chemical alterations 
of lipoproteins. All these factors may elevate the risk of atherogenesis Wright et 
al., 2006. 
 
2.3.1. ß-cell dysfunction in type 2 diabetes 
In subjects with type 2 diabetes, ß-dell dysfunction is occurring induced by 
hyperglycemia. This alteration is shown in decreased insulin response to 
intravenous glucose and reduced capability of glucose to enhance the insulin 
response to non-glucose fragments (amino acid arginine, hormones such as 
secretin, ß-adrenergic agonist isoproterenol). Additionally, changes have been 
recorded in pulsatile and oscillatory insulin release. However, a non-efficient 
formation of insulin and a decreased release of islet amyloid polypeptide, also 
called amylin, have been found in type 2 diabetes patients Kahn, 2003. It is 
proven that a decline of pancreatic ß-cell mass contributes to the degree of 
hyperglycemia. This decline can be explained by the simultaneous 
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sedimentation of amyloid. It is usually generated in ß-cells and secreted 
together with insulin. However, the exact mechanism for this process is still not 
fully understood. It might be appropriate to hypothesize that the deposited 
amyloid could be responsible for the advanced ß-cell failure observed in all 
treated type 2 diabetes subjects Porte et al., 2001. It is known that the loss in 
ß-cell function starts many years before the clinical diagnosis of diabetes. As 
mentioned, there are various factors that are responsible for the onset of the ß-
cell dysfunction such as hyperglycemia and also elevated free fatty acids, which 
contribute to the damage of ß-cells. Therefore attention has to be turned to the 
control of these parameters to ensure improved insulin secretion and even to 
prevent the progression of ß-cells dysfunction. Although a large number of 
therapeutic opportunities exist to decrease plasma glucose levels, still they are 
not able to slow down the loss of ß-cell function Kahn, 2001. 
 
2.3.1.2 ß-cell dysfunction and oxidative stress 
Antioxidative defense mechanisms of pancreatic ß-cells are notably low and are 
able to overcome by redox instability that emerges from overproduction of ROS 
and RNS. Consequently, this leads to lipid peroxidation, oxidation of proteins, 
DNA damage and the involvement of ROS/RNS with signal transduction 
pathways that induce considerably to ß-cell dysfunction Rhodes, 2005. 
Glucolipotoxicity is suspected to play an important role in ß-cell damage in Type 
2 diabetes whereas pro-inflammatory cytokines are considered not being 
involved in the disease Kahn, 2001.  Enhanced mitochondrial metabolic flow is 
necessary in the ß-cell to produce the ATP signal for glucose-caused insulin 
secretion and its intensification through fatty acids Butler et al., 2003. 
However, higher metabolic flow is supposed to enhance 02.- generation through 
the respiratory chain as high increased glucose and lipid levels results in 
decreasing the mitochondrial membrane potential through UCP2 (uncoupling 
protein 2) Bonner-Weir and Weir, 2005. This ought to lower metabolic flow 
through the respiratory chain and therefore decrease 02.- generation. Under 
these conditions it reacts as a protection against ROS-induced impairment but 
at the same time it weakens the nutrient-induced insulin secretion. It is 
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questionable if enhanced intramitochondrial production of ROS essentially leads 
to ß-cell damage in Type 2 diabetes. The intracellular milieu of the pancreatic ß-
cell contains high oxygen and glucose levels, which constitutes a low enzymatic 
antioxidative defence system and makes it vulnerable to oxidative stress, 
autoimmune attack and further glucolipotoxic offense Lenzen et al., 1996. 
However, an efficient inactivation of ROS in the ß-cell mitochondria might inhibit 
the signaling function of metabolism for nutrient induced insulin secretion. ROS 
lead to ß-cell dysfunction in Type 1 and Type 2 diabetes, although the 
underlying mechanisms are very different Lenzen, 2008. 
 
2.3.2 Biomarkers of oxidative stress in diabetes mellitus 
Remarkably increased levels of free radicals and at the same time a decrease 
in the antioxidant defense system might cause an impairment of cellular 
organelles and enzymes, enhanced lipid peroxidation and consequently 
generate insulin resistance. These consequences are leading to changes in 
oxidative stress biomarkers as there are superoxide dismutase, glutathione 
reductase, catalase, glutathione peroxidase, vitamins, glutathione levels, lipid 
peroxidation markers such as malondialdehyde, nonenzymatic glycosylated 
proteins, nitrite concentration, glycosylated proteins, and of course 
hyperglycemia Maritim et al., 2002. Laboratory reports of oxidative damage 
and antioxidant resistance would be needed in health screening, preventive 
medicine, risk assessment and disease forecast and further for dietary or drug 
therapy Yang et al., 2011.  
 
2.3.2.1 Lipid peroxidation  
Lipid peroxidation (LPO) is a well-known mechanism playing a role in aging, 
atherosclerosis and late complications of diabetes mellitus. LPO products are 
instable marker of oxidative stress that decay to form complex, reactive by-
products. The most common by-products of lipid peroxidation are 
malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and 8-iso-prostaglandin 
F2- (8-isoprostane). MDA is a product caused by peroxidation of arachidonic, 
eicosapentaenoic and docosahexaenoic acids Nakhjavani et al., 2010. 
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2.3.2.2 Malondialdehyde in diabetes mellitus 
MDA represents one of the most important secondary oxidation products of 
peroxidized polyunsaturated fatty acids. It has been well documented that MDA 
is potentially participating in the outbreak of atherosclerosis Suttnar et al., 
2001. MDA has been detected at higher levels in different diseases and 
presumed to be involved in free radical damage. Therefore MDA has been 
widely used as a biomarker for the analysis of LPO. Further, MDA is also 
applied in food science as marker of lipid oxidation and rancidity in foods and 
food products Janero et al., 1990. MDA is mostly identified 
spectrophotometrically as thiobarbituric acid reactive substances (TBARS) after 
it has reacted with thiobarbituric acid at 100 °C in acidic milieu. Generally it is an 
uncomplex and cheap method, however, possibly inaccurate since TBA reacts 
also with various other substances (e.g. carbohydrates, amino acids, pigments, 
pyridins, etc.) and not specifically with MDA-oxidants. Consequently, these 
other compounds interfere in the TBA analysis and lead to a variability in the 
results. Nevertheless, it remains a popular method since the positive aspects 
outcome the negative ones, particularly when using the more specific UPCL 
method. Increasing evidence suggest that MDA-levels are significantly higher in 
subjects with diabetes type 2 Mateos et al., 2005. However, there are many 
contradictory outcomes in literature about serum MDA levels in subjects with 
diabetes. Some have shown increased and others similar levels in diabetes 
patients when compared with healthy subjects Pasaoglu et al., 2004. 
  
2.3.2.3 NF-kB (nuclear factor 'kappa-light-chain-enhancer' of activated B-
cells) 
Oxidative stress-linked inflammation is associated with triggering early vascular 
damages in atherogenesis, intergrating the adjustment of vascular adhesion 
fragments and matrix metalloproteinase activity. These processes need the 
activation of NF-kB, a transcription factor that involves the expression of 
numerous genes implicated in inflammation and endothelial cell decline. As an 
inhibitor of NF-kB -Lipoid acid (-LA) is widely accepted Packer, 1998. 
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However, -LA restricts the tumor necrosis factor-alpha (TNF-α), which is 
provoked by NF-kB activation and adhesion fragments expression in human 
aortic endothelial cells through a mechanism apparently different from 
conventional endogenous antioxidants like ascorbate or reduced GSH. 
Furthermore, -LA /DHLA (DiHydroLipoic Acid, which is the reduced form of -
LA), might be able to decrease the proinflammatory conditions by its interplay 
with NF-kB Zhang and Frei, 2001. Furthermore, superoxide anions uprising 
through hyperglycemia, activate NF-kB, which leads to enhanced expression of 
inducible nitric oxide synthase (iNOS). This elevation in iNOS leads to an 
amplified production of NO. When O– · levels are high, they react fast with 
generated NO to form the strong oxidant peroxynitrite, which is toxic to 
endothelial cells Beckman and Koppenol, 1996. However, as a consequence 
of NF-kB activation, the expression of a number of cytokines is elevated, 
including tumour necrosis factors (TNF-α and further TNF-,) interleukins (IL) 1, 
6, 8 and 18 and interferon-, which has been reported to occur in high 
concentrations in type 2 diabetes subjects Wright et al., 2006.  
 
2.3.3 Enzymatic Antioxidants 
High glucose levels may result in an elevation of both activity and expression of 
antioxidant enzymes (Cu, Zn-superoxide dismutase, glutathione peroxidase, 
catalase). This expression of antioxidant enzymes could also be explained by 
glucose-induced oxidative stress Ceriello et al., 1996. Thus, there have been 
contradictory results regarding increased or decreased antioxidant enzymes in 
diabetes.  
 
2.3.3.1 Superoxide dismutase 
The superoxide dismutases (SODs) are one of the most important antioxidant 
enzyme defense systems against ROS and especially superoxide anion 
radicals. The superoxide dismutase represents the first line of defense against 
ROS within a cell. O2- is generated wherever an electron transport chain is 
present, and however, O2 activation is given in different compartments of cells. 
Consequently SODs exist in all the cell’s compartments too Alscher et al., 
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2002. Superoxide is an anion and not able to move far from its site of formation 
due to lipophilic membrane obstacles. SOD converts superoxide into hydrogen 
peroxide, which is a small molecule, unloaded, and diffuses willingly within and 
between cells. So far, three clear isoforms of SOD have been found in 
mammals. Two isoforms of SOD include Cu and Zn in their catalytic center, 
called CuZn-SOD or SOD1. Another form of SOD has manganese (Mn) as a 
cofactor and has been found in mitochondria of aerobic cells. It is also called 
SOD2. In EC-SOD, also called SOD3, the catalytic center is localized to 
extracellular elements Zelko et al., 2002.  
 
2 O2- + 2 H+   H2O2 + O2  Zelko et al., 2002 
 
 
Hydrogen peroxide is not exceedingly reactive and is able to accumulate. 
Concentrations of 100 µmol/l or even higher have been found in biological fluids 
Halliwell et al., 2000. This quite great amount might reflect ex vivo or post-
production changes in these compartments rather than the true in vivo levels, 
however, considerable levels are probably existing in vivo. This constitutes a 
potential threat to biological systems due to the fact that hydrogen peroxide 
reacts with reduced metal ions in the Haber-Weiss reaction and results in 
hydroxyl radicals. The latter are extremely reactive and cause a fast and 
indiscriminate impairment to biological substrates Benzie, 2002.  
Superoxide is presumed to be involved in increased glucose levels Kanwar et 
al., 2007. The activity of SOD was decreased in diabetic patients. The decline 
in SOD activity could be due to an inactivation by H2O2 or by glycation of the 
enzyme, which has been found in diabetes Sozman et al., 2001. However, 
different results have been found in various studies on SOD concentrations in 
diabetics. Human extracellular superoxide dismutase might be glycated, which 
is linked to a decline in its affinity for heparin voidly, which is influencing its 
enzymatic activity. The amount of glycated EC-SOD is distinctly higher in 
diabetic subjects than in healthy ones. The amount of EC-SOD on the surface 
of the endothelium might be declined, which increases the vulnerability of cells 
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to superoxide radicals generated in the extracellular compartments Adachi et 
al., 1992.  
 
2.3.3.2 Glutathione peroxidase and Glutathione reductase 
Glutathione peroxidase and reductase are enzymes that occur in the cytoplasm, 
mitochondria and nucleus under in vivo conditions. GSH plays an important role 
as antioxidant in humans. Glutathione peroxidase converts hydrogen peroxide 
to water with reduced glutathione as hydrogen donor Montarana et al., 1997.  
 
H2O2 + 2 GSH  2H2O + GSSG Montarana et al., 1997 
 
 
Glutathione disulfide is reduced to glutathione by glutathione reductase, by 
using the cofactor NADPH, which is produced by glucose-6-phosphate 
dehydrogenase.  
 
GSSG + NADPH  GSH+NADP Montarana et al., 1997 
 
However, there are contradictory outcomes on diabetes and enzyme activities 
Maritim et al., 2002. A decline in GSH was discussed as an enhanced 
utilization due to oxidative stress. On the other hand it has been suggested that 
plasma GPH-Px activity is enhanced in both types of diabetes. The increased 
activity in GSH-Px has also been reported in diabetic subjects with retinopathy, 
which might constitute a compensatory mechanism to inhibit tissue impairment 
Rema et al., 1995.  
 
2.3.3.3 Catalase 
The enzyme catalase is found in peroxisomes and converts hydrogen peroxide 
to water and oxygen.  
 
2 H2O2  O2 + 2 H2O Maritim et al., 2002 
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Consequently, catalase defends pancreatic ß-cells from impairment by H2O2. It 
has been reported that diabetes is linked with catalase deficiency. In model 
systems with normal catalase production, the activity of this antioxidant enzyme 
has been reported being enhanced in response to oxidative stress and 
protecting pancreatic ß-cells Maritim et al., 2002.   
 
2.3.4 Non-enzymatic antioxidants  
Serum or dietary vitamin A, E, and C levels have been hypothesized to be lower 
in people with impaired glucose tolerance or with type 2 diabetes compared to 
those with normal glucose tolerance. However, there is conflicting proof 
regarding these relations Montonen et al., 2004. Experimental animal models 
have shown that antioxidant supplementation delay the onset of type 2 diabetes 
and therefore hypothesized that supplementation may help preventing the 
development of the disease in humans. A large, randomized, double-blind, 
placebo-controlled study did not find a significant overall effect of vitamin C and 
E and ß-carotene on risk of type 2 diabetes in women with high risk of 
cardiovascular disease Song et al., 2009. 
 
2.3.4.1 Vitamin E 
Vitamin E is an important lipid-soluble chain-breaking antioxidant with anti-
inflammatory character. In vitro studies reported that vitamin E may improve 
insulin action and insulin secretion by defending peripheral tissues and ß-cells 
from free radical-mediated impairment. This leads to the hypothesis that vitamin 
E may support delay the development of type 2 diabetes Liu et al., 2006. 
Prospective epidemiological studies showed that high serum vitamin E levels 
are linked to decreased risk of NIDDM. Vitamin E supplementation significantly 
improved glycemic control in a rat with NIDDM. This outcome was explained by 
the possible ability of the vitamin to minimize free radical damage to the 
pancreatic ß-cells Ihara et al., 2000. 
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2.3.4.2 Vitamin C 
Vitamin C has also been investigated in diabetes mellitus. It is essential in 
regenerating vitamin E from the -tocopheroxyl radical. It has been reported 
that vitamin C plasma levels are unchanged in type 1 and type 2 diabetic 
subjects Bonnefont-Rousselot et al., 2000. Vitamin C is an important 
antioxidant in the extracellular compartments. It scavenges efficiently 
superoxide, H2O2, hydroxyl-radicals, hypochloric acid, singlet oxygen and other 
reactive substances Elmadfa und Leitzmann, 2004. 
 
2.3.4.3 -Lipoic acid  
Due to chemical reduction and oxidation capacity of -LA, it has been reported 
that it may play a role in the antioxidant defense system. Petersen Shay and 
colleagues reported that -LA and its reduced form, dihydrolipoic acid (DHLA), 
straightly scavenge reactive oxygen species and further reactive nitrogen 
species. Furthermore it defends cells against a number of attacks where 
oxidative stress plays an important role. Yet there is little proof that -LA 
generates this impact by its antioxidant effect or by its impact on cell signaling 
pathways that keep the endogenous antioxidant capacity. The biggest proof for 
diet-based -LA as a therapy has been tested on type 2 diabetes subjects. -
LA is used in Germany for over 3 decades in the treatment of diabetic 
polyneuropathies Evans and Goldfine, 2000. Further on, a great number of 
experimental proofs exist which support a role for -LA as a compensator for 
oxidative stress in diabetes Nagmatsu et al., 1995. Various reports also reveal 
that -LA enhances glucose regulation in subjects with type 2 diabetes. Animal 
studies demonstrate that -LA upgrades skeletal muscle glucose uptake, 
amends body glucose tolerance, and is auxiliary against insulin resistance 
Jakob et al., 1996. -LA’s positive contribution regarding the enhanced 
glycemic control might come from its synergism with regulatory parts of the 
insulin signaling cascade Petersen Shay et al., 2008. 
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2.3.4.3.1 -LA as an activator of base disposability for GSH synthesis 
-LA may even increase the expression of enzymes involved in GSH 
generation and furthermore also increase GSH concentrations through its 
capability to enhance cysteine uptake. Studies have demonstrated that DHLA 
declines intracellular cystine to cysteine when administered to cultured cells, 
consequently enhancing the rate of GSH generation, as cysteine constitutes the 
rate-terminating base for the reaction Han et al., 1997. Diet-deduced -LA 
might increase both GSH synthetic capacity and intracellular concentrations of 
cysteine. These outcomes indicate that one diet-related mechanism from -LA 
improves the cellular antioxidant capability might be by induction of endogenous 
antioxidants (e.g. GSH). This maintains its antioxidant influence far longer than 
-LA is be prevailing as a direct scavenger of ROS/RNS Suh et al., 2004.  
 
2.3.4.4 Ubichinone (Coenzym Q10) 
Coenzyme Q10 (CoQ) constitutes a lipid-soluble compound formed primarily 
from endogenous synthesis. It is important as it plays a role as an electron 
carrier in mitochondrial oxidative phosphorylation and might even have an 
essential role as an antioxidant Eriksson et al., 1999. The outcomes of 
controlled intervention trials, which have determined the influence of CoQ on 
glycemic control in diabetic patients, are incongruous Singh et al., 1999. CoQ 
might be able to decrease oxidative stress by restraining production of 
superoxides through mitochondria. This is a factor that could be primarily 
relevant in diabetic subjects. However, studies suggest that the 
supplementation of CoQ decreases blood pressure and upgrades long-term 
glycemic control in type 2 diabetic patients Nishikawa et al, 2000.  
 
2.3.4.5 Carotenoids    
Carotenoids are a heterogenous group of elements provided by plants. The 
main ones that are found in serum are -carotene, -carotene, -
crypthoxanthin, lutein/zeaxanthin, and lycopene Coyne et al., 2005. Serum or 
dietary vitamin A, E, and C levels have been assumed to be minor in subjects 
with impaired glucose tolerance or with type 2 diabetes, than in those with a 
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normal glucose tolerance Montonen et al., 2004. Various cross-sectional 
epidemiological trials have revealed an inverse association between serum 
carotenoids and diabetes status even though intervention trials with isolated 
supplements of antioxidant vitamins have shown contradictory outcomes Ford 
et al., 1999. Clinical studies on the basis of diets with carotenoid-rich 
vegetables and fruits might be able to support with essential insight in relation 
not only to the prophylaxis of complications of diabetes, but also to lower the 
risk, particularly among those with impaired glucose tolerance Coyne et al., 
2005.  
 
2.3.4.6 Flavonoids   
Flavonoids are a wide family of polyphenolic compounds generated by plants 
with a smaller chemical structure. Polyphenolic compounds, or polyphenols are 
polyhydroxylated phytochemicals and include the two major classes flavonoids 
and phenolic acids. Flavonoids can be further divided into various subclasses, 
as there are flavones (and also isoflavones), flavanones, flavanols (catechins), 
flavonols and anthocyanidins Lotito and Frei, 2006. Consumption of flavonoid-
abundant foods and vegetables, is associated with a lower incidence of heart, 
disease, cancer, ischemic stroke and other chronic diseases Riboli and Norat, 
2005; Bosetti et al., 2005. Due to the fact that these chronic diseases are 
linked to oxidative stress and flavonoids are strong antioxidants in vitro, it has 
been reported that dietary flavonoids provide health benefits through antioxidant 
mechanisms Serafini et al., 2000. Despite the fact that there is contradictory 
proof whether intake of flavonoid-rich foods leads to elevated antioxidant 
protection of macromolecules in plasma and LDL, a large number of studies 
have shown an increase in the total antioxidant capacity of plasma in humans. 
Consequently, this finding substantiates the hypothesis that flavonoids, and 
polyphenols commonly, play an important role as antioxidants in human blood 
and tissues Lotito and Frei, 2006. Various small, scale dietary intervention 
studies have reported that consumption of flavonoid-abundant foods were 
linked with a substantial increase in plasma levels of flavonoids in diabetic 
patients Holman and Katan, 1999. Flavonoids play a role as free radical 
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scavengers and strong metal chelators Lean et al., 1999. Furthermore, 
flavonoids might be able to protect ß-cell damage by lowering oxidative stress-
linked tissue impairment and therefore protect against the progression of insulin 
resistance in type 2 diabetes Knekt et al., 2002. Yet, the connection of dietary 
flavonoids regarding the development of type 2 diabetes is still not quite proven. 
However, future studies are needed to explore whether flavonoid-rich 
compounds other than flavonols and flavones are able to protect against the 
onset of type 2 diabetes or its complications Song et al., 2005.  
 
2.3.4.7 Glutathione GSH  
Reduced glutathione is the main omnipresent and richly available antioxidant 
within human cells to fight damage induced by oxidative stress. GSH constitutes 
a tripeptide generated from glutamate, cysteine and glycine in two steps 
catalyzed by -L-glutamyl-L-cysteine:glycine ligase and glutathione synthetase. 
Diabetes is associated with reduced cellular glutathione levels. The reason for 
this low GSH activity has not been found so far Whiting et al., 2008. 
Mechanisms, which are involved in tissue impairment caused by hyperglycemia 
in diabetes have different signaling through protein kinase C, increased 
advanced glycation end products and the aldose reductase pathway. ROS are 
acquainted to trigger these pathways by activation of aldose reductase, protein 
kinase C isoforms, NF-kB, induction of diacylglycerol and formation of advanced 
glycation endproducts development. Declining concentrations of mitochondrial 
ROS (and thereby oxidative stress) effectively protects activation and induction 
of these mechanisms Nishikawa et al., 2000.  
 
2.3.5 Effects of diet on patients with type 2 diabetes mellitus  
It is well-reported that obesity and physical inactivity are the main risk factors for 
type 2 diabetes, besides the genetic predisposition. However, recent proofs 
indicate that oxidative stress is involved in the pathogenesis of type 2 diabetes 
by enhancing insulin resistance or damage insulin secretion. Yet, diet is thought 
to have crucial impact on the development of diabetes. Dietary antioxidants 
have been assumed to protect against the onset of diabetes by delaying 
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oxidative chain reactions Montonen et al., 2004. Therefore it seems to be selv-
evident that an adequate intake of antioxidants has an impact on the onset of 
type 2 diabetes. However, little epidemiological proof is existing on the role of 
dietary antioxidant to reduce the incidence of type 2 diabetes. Although the 
importance of diet in the etiology of diabetes has long been investigated, no 
specific nutrient, food or diatary pattern has been found to reduce the risk for 
diabetes mellitus Feskens et al., 1995. Interestingly, most dietary factors 
affecting diabetes risk have adverse effects on biomarkers of cardiovascular 
risk and inflammation. The importance of diet in the therapy of diabetes has 
been discussed in various reviews, but only few have focused on the prevention 
of diabetes Buyken at al., 2010. Recommendations to enhance fruit and 
vegetable intake to five servings per day are well-known tools of health 
promotion programs. Increased consumption of vegetables and legumes was 
inversely linked to 2h glucoses level in a prospective study of middle-aged men 
Feskens et al., 1995. Risk of diabetes was also inversely associated to 
vegetable, but not fruit intake in the Nurses’ Health Study Colditz et al., 1992. 
Further, Williams et al. (1999) reported that frequent consumption of salad 
vegetables is linked to a decreased risk for type 2 diabetes.  Fruit and salad 
vegetables are good dietary sources of vitamin C Paolisso and Giugliano, 
1996. The EPIC-Norfolk Study concluded that glycosylated hemoglobin, 
HbA1c, was inversely associated with plasma vitamin C levels Sergeant et al., 
2000. Furthermore according to Sergeant et al, subjects who never or rarely 
eat fruits or green leafy vegetables have the highest mean HbA1c levels 
compared to subjects with appropriate consumption. This was the case in both 
genders and uninfluenced by the possible confounders age, WHR, BMI, 
smoking, family history of diabetes, alcohol consumption, intake of dietary 
supplements, educational status, vegetarianism, leisure-time physical activity 
and total energy intake. However, the mean HbA1c in the category of fruit and 
green leafy vegetable intake were not considerably changed after adjustment 
for saturated fat consumption, dietary fibre, dietary vitamin C and plasma 
vitamin C status. Diets characterized by high fat and low carbohydrate 
consumption have been linked to diabetes in cross-sectional and retrospective 
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study from Hamman (1992). A large, prospective study of middleaged Chinese 
women reported that a higher consumption of vegetables is linked to a 
decreased risk of type 2 diabetes, whereas fruit consumption was not 
associated Villegas et al., 2007. According to a randomized control trial with 
577 participants with impaired glucose tolerance that was carried out in China, a 
diet rich in fruits and vegetables decreased the incidence of type 2 diabetes by 
24% Pan et al., 1997. A couple of studies examined vegetable groups and the 
risk of T2D. It was detected that a yellow and dark-green vegetable 
consumption is linked to reduced HbA1c levels and the incidence of type 2 
diabetes Lui et al., 2004. A cross-sectional study with native Canadians 
reported a protective impact of vegetables in subjects with impaired glucose 
tolerance or type 2 diabetes Gittelsohn et al. 1998. Furthermore, another 
cross-sectional study, which has been performed in the UK reported an 
association between the risk of type 2 diabetes and salad and raw vegetable 
intake after adjustment for sex, age and family history of type 2 diabetes. But 
when data were adjusted for BMI, the link dropped in this study. The 
mechanisms by which vegetables interfere with glucose tolerance have not 
been detected yet but the reason could be the high conent of antioxidants, fiber 
and magnesium or further the low glycemic index Williams et al. in 1999. 
However, chronic intake of vitamin E has been associated with improved insulin 
sensitivity and vitamin C with increased insulin action in both healthy and 
diabetic subjects Villegas et al., 2007. In accordance with Villegas et al. the 
inverse link between vegetable intake and T2D lasted after adjustment for 
vitamin C, vitamin E, carotene and fiber consumption. Considering this it seems 
that the positive effects of vegetable consumption on the risk of type 2 diabetes 
cannot be completely linked to antioxidant vitamins, magnesium or fiber 
consumption. Certainly, vegetables also comprise other ingredients such as 
lignans, phytates and isoflavones that might have an additive or synergistic 
impact on decreasing the risk of type 2 diabetes.  Furthermore, the link between 
processed meat intake and the development of diabetes has been detected in 
various studies. The reason for the link might be given due to cholesterol, 
saturated fat and nitrites. The type and quantity of fat consumed may also have 
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an impact to the onset of diabetes Costacou and Mayer-Davis, 2003. Various 
studies have reported that an increased intake of polyunsaturated fat and 
potentially long-chain n-3 fatty acids may be beneficial in the prevention of type 
2 diabetes, whereas increased consumption of saturated fat and trans-fat show 
adverse effects Hu et al., 2001b. Montonen et al. reported that margarine and 
oil consumption is linked to a decreased diabetes risk. This is in accordance 
with a previous epidemiological study that have reported a link between the 
consumption of vegetable fat and declined diabetes risks Salmeron et al. 
2001. The type of dietary fat may play a role in the diabetes onset by altering 
the fatty acid structure of the phospholipid cell membrane, which may have an 
impact on insulin receptor quality and glucose transport Storlien et al., 1991.  
 
2.3.5.1 Effects of n-3 fatty acids on type 2 diabetes mellitus 
The increased interest for the consumption of n-3 (polyunsaturated) fatty acids 
in vascular disease is due to results obtained from studies in Inuits (Eskimos) in 
Greenland showing a lower appearance of coronary heart disease (CHD) in 
these populations compared with the Scandinavian control group Schmidt, 
1997. It has been reported that Inuits have diminished platelet reactivity and an 
extended bleeding time compared with a Scandinavian control group. This was 
ascribed to the Eskimo diet which is rich in fish or fish-derived products, rich in 
n-3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) Bang, 1980. Further, inverse association between fish consumption 
and mortality from CHD in Japanese and Alaskans were found. Yet, in Western 
populations with a rather poor intake of n-3 fatty acids, both protective and no 
effects of n-3 fatty acids on CHD have been detected Albert et al., 2002. 
Diabetes subjects have a three-to fourfold increased risk of CHD compared with 
the common population. Fonoseca et al. (2004) reported a suitable benefit of  
n-3 fatty acids to diabetes patients, where the necessity for “nontraditional” 
precautious or therapeutic methods is even greater than for cardiovascular 
diseases in general. 
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2.3.5.2 Structure and mechanisms of n-3 fatty acids 
Fatty acids are organic acids with an aliphatic chain and a carboxyl group. The 
aliphatic chain can be all saturated, for example containing only single bonds, or 
unsaturated, with one (monounsaturated fatty acids) or more double bonds 
(polyunsaturated fatty acids, short form PUFA). There are two different series of 
PUFAs: the n-6 family (n-6 fatty acids), formed from linoleic acid (LA) as a 
metabolic precursor, and the n-3 fatty acids deducing from -linolenic acid (-
LNA). LA and -LNA are called “essential” since humans (and mammals in 
general) are not capable to produce them and must therefore be supplied with 
food Seo et al., 2005. LA occurs widely in vegetable oils. Canola oil, rapeseed 
oil, linseed oil and walnut oil however, contain high amounts of -LNA. n-6 and 
n-3 fatty acids constitute elemental parts of phospholipids in cell membranes. 
They are able to be released primarily through the influence of phospholipase 
A2 and then converted through reactions catalyzed by cyclooxygenases and 
lipooxygenases to eicosanoids (including prostaglandins, leukotrienes (LT) and 
thromboxanes) (Fig. 3). Enhancing n-3 fatty acids in the diet leads to their 
fractional compensation of fatty acids of the n-6 series, and consequently 
lowering the relative amount of arachidonic adid (AA) in the cell membrane 
phospholipids Serhan et al., 2004. This entails a lower production of 
prostanoids and promotes the generation of rather weaker prostanoids 
(especially for thromboxane TX A3 and TXA2) or as newly detected, anti-
inflammatory prostanoids. Furthermore, the increase in vascular generation of 
nitric oxide or the lowered expression of cytokines, tissue consideration and 
growth factors may have an important influence in the vasoactive answers 
initiated by dietary n-3 fatty acids Schmidt, 2003. AA and EPA constitute 
substrates in leukocytes and monocytes for the generation of LT. LTB4, formed 
from AA, has strong chemotactic and other leukocyte-activating properties, 
while sulfido-peptide LT (LTC4, LTD4 and LTE4) acts vasoconstrictive and can 
elevate vascular permeability. By the use of 5-lipoxygenase, EPA increases the 
LT of the 5-series, such as LTB5, LTC5, LTC5 and LTE5, which have lower 
proinflammatory and vasoconstrictive than those of the 4-series.  
 
  
29
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Metabolism and nomenclature of the major PUFAs of the linoleic series (left) 
and the -linolenic series (right). The biosynthetic track is driven by the reactions of 
elongase and desaturase (5 and 6) and increases eicosanoids with specific 
biological characteristics De Caterina et al., 2007. 
 
2.3.5.3 Effects of n-3 fatty acids on diabetes  
The major effects of dietary n-3 fatty acids on plasma lipids and lipoproteins is 
mainly a decrease in plasma triglycerids by 20-50% in healthy subjects and 
even higher in subjects with hypertriglyceridemia, including diabetic subjects. 
The effect is dose dependent but usually only after consumption of n-3 fatty 
acids higher than 2-3 g/day. The decreasing effect of triglycerides due to n-3 
fatty acids is explained by a declined hepatic synthesis of VLDL, although Harris 
has also announced an elevation of hepatic-VLDL. In a double-blind, 
randomized, placebo-controlled study in subjects with insulin resistance and 
visceral obesity, the effect of n-3 fatty acids on apolipoprotein (apoB) 
metabolism was examined. According to this study the n-3 fatty acids 
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efficaciously decreased the triacylglycerol levels due to the lowered VLDL apoB 
generation, without modifying the catabolism of apoB-including lipoproteins or 
chylomicron residues Chan et al., 2003. Furthermore, in a randomized double-
blind crossover study with type 2 diabetic patients, a substantial decline in 
serum concentrations of apoB was determined after a daily intake of 3 g of EPA 
ethyl esters during two successive 8-week periods Boberg et al., 1992. The 
reason of the sometimes observed enhanced LDL and HDL cholesterol in 
diabetic subjects could be due to the development of smaller VLDL particles 
limited in triglyderides. These are extricated from the circular flow more steady 
than bigger VLDL and therefore more likely transformed into LDL Packard, 
2003. The decrease of VLDL generation and the alteration in their composition 
may enhance not only their catabolism, but also the impact of their 
transformation to intermediate-density lipoprotein and LDL. However, smaller 
VLDL could be due to the hepatic secretion of triglyceride-poor VLDL and an 
elevated activity of lipoprotein lipase towards n-3 fatty acids-enriched 
triglycerids. It is conceivable that LDL including these fatty acids is less 
atherogenic, since they are less susceptible to oxidative transformations Appel 
et al., 1993. However, the capability of unsaturated fatty acids in general, and 
n-3 fatty acids in detail, to lower the activation of NF-kB-reliant proinflammatory 
genes seems to be linked to the number of double bonds in the fatty acid chain 
De Catarina et al., 1998.  
 
2.3.5.4 Effects of n-3 fatty acids on insulin resistance 
A PUFA-rich diet, especially rich in n-3 fatty acids, has been reported to have 
antiobesity effects and further support insulin action through various metabolic 
effects. Consumption of both n-6 (linoleic acid) and n-3 fatty acids has been 
lead to smoother hepatic lipogenesis, decline in the hepatic triglycerides, 
synthesis elevate ketogenesis, and decreased fatty acid oxidation in both the 
liver and the skeletal muscle. Insulin sensitivity may improve due to the effects 
of fatty acid consumption on membrane fluidity Podolin et al., 1998. The 
change in glucose uptake after membrane increase with PUFA is obviously 
linked with increase in the residency time of GLUT4 in the plasma membrane. 
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This results in higher intracellular store of glucose-6-phosphate and on 
enhanced skeletal muscle glycogen generation Power et al., 1997. These 
metabolic efficiencies on insulin sensitivity and glucose metabolism due to n-3 
fatty acid intake can be substantiated as a consequence of particular alteration 
of serum fatty acid structure Vessby et al.,1994.  
 
2.3.5.5 Effects of oil intake on type 2 diabetes  
The link between dietary consumption of oleic acid and insulin resistance is not 
fully understood. An association between insulin resistance and concentrations 
of some monounsaturated fatty acids has been reported, such as palmitoleic 
acid. However, studies of oleic acid have shown contradictory results Lovejoy 
et al., 2001. Some studies have reported a decline in insulin resistance with a 
diet high in oleic acid, but others have either shown no relationship or an 
inverse link between oleic acid and insulin sensitivity Ryan et al., 2000. The 
level of oleic acid is very high in tissue membranes, such as muscle or liver 
where the application of insulin is crucial and alterations in these levels have an 
impact on cell membrane fluidity and functionality and might further affect 
peripheral insulin sensitivity Soriguer et al., 2004.  
 
2.3.5.6 Nuts and health benefits 
Nuts (tree nuts and peanuts) are dense foods with complex structures rich in 
unsaturated fatty acids and other bioactive components such as phytosterols 
and phenolic substances. Further it consists of high-quality vegetable proteins, 
minerals, tocopherols and fiber. Due to their unique ingredients nuts have 
beneficially effects to human health. Epidemiological studies have linked the nut 
intake with a lowered risk of coronary heart disease and gallstones in both 
genders and in diabetic women Ros, 2010. However, it has also been 
suggested to have positive effects on hypertension, inflammation and cancer. 
Intervention studies have reported that nut intake shows a cholesterol-lowering 
effect and favorable effects on oxidative stress and vascular reactivity Kendall 
et al., 2010. Walnuts differ in the composition from other nuts due to their 
greater amounts of polyunsaturated fatty acids (and particularly high ALA 
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content) and antioxidants particularly as -tocopherol. Nut intake has also been 
inversely linked to the risk of type 2 diabetes in women Jiang et al., 2002. A 
low-fat diet with walnuts has been reported to decrease total cholesterol 
(compared with a normal or low-fat diet) and LDL concentration (in contrast to a 
low-fat diet alone). However, no effects on triglyderides were detected Almario 
et al., 2001. There are not many studies published about the health effects of 
walnut oil or positive effects on diabetes parameters so far. Although it may be 
presumed that, considering the positive effects of walnuts, walnut oil might have 
positive impact too.  
 
Therefore walnut oil has been used together with various colored vegetables in 
the intervention study “Diaplant” in order to explore possible health benefits in 
metabolic parameters of type 2 diabetes subjects.  
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3. Materials and Methods 
 
3.1 Study design 
The “Diaplant” study is an epidemiological, prospective, randomized 
intervention study, which has been approved by the ethics commission of the 
city of Vienna and conducted at the Department of Nutritional Sciences. The 
project was realized in cooperation with the Health Centre Vienna (Wiener 
Gebietskrankenkasse). Interested participants were invited to information 
events, where all the details on the study and the nutritional intervention have 
been provided. Furthermore they received information about the benefits of a 
healthy diet. Subjects were randomly assigned to the information or intervention 
group which received 300 g of vegetables and 25 ml of a plant oil rich in 
polyunsaturated fatty acids per day for 8 weeks. 
 
Fasting blood samples were taken at baseline (T_0), after 4 weeks (T_1) and 
after 8 weeks (end of intervention T_2). The last blood samples were taken at 
week 16, after the participants consumed their usual diet for 8 weeks. 
Furthermore, anthropometric measurements (BMI, WHR) were conducted and 
the questionnaires  (FFQ, insulin report, QLQ, 24-h-recall) were filled. 
Additionally, the subjects were asked to keep a nutrition diary. The diabetic 
subjects were also asked to submit their glycaemic profile and their insulin 
protocol.  
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3.1.1 Classification of the participants 
 
 
Fig. 4: Classification of participants 
 
3.1.2 Subject recruitment 
The recruitment has been carried out by medical doctors at the Diabetes Center 
during the “diabetes day” and by an enclosure in a journal of the Austrian 
Diabetes Association. Doctors at the Health Centre Vienna South informed 
subjects that met the inclusion and exclusion criteria and invited those to the 
informational events. 10 of these information events took place in the Health 
Centre Vienna South and further two information lectures were held at the 
Austrian Diabetes Association. 130 people have been participating at these 
events and further 21 people have been informed by telephone. Finally, 120 
subjects signed the informed consent and 111 people started the study. 99 
completed it out of them. 35 were treated with insulin (IDDM), 41 with oral 
antidiabetics (NIDDM) and 23 reported being healthy. 12, out of 23 healthy 
subjects had increased fasting glucose levels and seem to have pre-diabetes. 
Therefore they were assigned to the “impaired fasting glucose (IFG)-group” (Fig 
4). 
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3.1.3 Criteria for choosing subjects 
 
Inclusion criteria: 
o Men and women with type 2 diabetes between 40 to 80 years of age 
o Treatment with oral antidiabetic or insulin 
o At least 4 weeks before study begin: 
Constant medication regarding glucose, fat and uric acid metabolism 
Constant diet habits and physical activity 
Constant body weight 
o HbA1C ≤ 9,5 % (fluctuation < 10 %) 
o Cholesterol < 300 mg/dl (with or without medication) 
o Serum triglyceride levels < 500 mg/dl (with or without medication) 
o Creatinin < 2,5 mg/dl 
o Medication of the NIDDM-group: Metformin, Sulfonyl uric acids, GLP-1 
Mimetika, DPP-IV-blocker 
o Medication of the IDDM-group: Insulin or Insulin plus Metformin 
 
Exclusion criteria: 
o Type 1 diabetes 
o Subjects younger than 40 and older than 80 
o Smoker 
o Pregnant or breast feeding women 
o Participants in other clinical trials 
o New medication or changes in the medication regarding glucose, fat and 
uric acid metabolism 4 weeks before begin of the study 
o Intake of fish oil supplements or other fatty acids 
o During or before starting the study intervention to change dietary habits, 
physical activity or body weight 
o Cardio vascular diseases, classified after NYHA-classificaiton ≥ III 
o Liver diseases (transaminase threshold ≥ 2,5 fold increased) 
o Chronical renal insufficiency (dialyses patient or creatinin > 2,5 mg/dl 
o Organ transplantation 
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o Gastrointestinal malabsorbtion (pancreatic insufficiency, steatorhoe, 
short bowl syndrom) 
o Systemic steroids 
o Drug or alcohol abuse (≥ 80 g/d); Methadone intake during last 2 years 
o Cancer, HIV 
o Glitazon intake 
 
3.1.4 Vegetables and plant oil characteristics 
In table 3 the list of vegetables are listed, which were provided by Iglo Austria. A 
plant oil rich in PUFA and -tocopherol was used. The oil characteristics are 
shown in table 4. 
 
Broccoli Crème spinach with potato fritters 
Brussels sprouts Green beans 
Turnip cabbage  Soya beans 
Carrots  Peas 
Cauliflower Soup vegetables 
Cos lettuce  Summer vegetables 
Colorful vegetable trio Roasted vegetables “Korsika” 
Courgette Roasted vegetables “Gärtnerin” 
 
Tab. 3: List of vegetables, which were used in the study 
 
Total fatty acids (%) Mean value  sd 
c16:0 7.28     0.09 
c18:0 2.06     0.07 
c18:1n9c 16.40   0.99 
c18:1n7c 0.950   0.03 
c18:2n6c 61.76   1.00 
c18:3n3 11.49   0.43 
  
Tocopherol content (mg/100g oil) Mean value  sd 
-Tocopherol 32.98  1.82 
-Tocopherol 2.67    0.14 
 
Tab. 4: Oil characteristics of the “study oil” 
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3.1.5 Blood preparation 
The participant’s fasting blood was taken and put in Heparin-, EDTA- and serum 
test tubes, which were centrifuged for 10 minutes at 3000 rpm. The plasma was 
transferred into Eppendorf cups, treated with nitrogen gas and stored at – 80 °C 
until it was used for analysis.   
 
3.2 Malondialdehyde 
 
3.2.1 Principle of the method 
The plasma is hydrolysed with phosphoric acid to form a color complex with 
thiobarbituric acid during the 1 hour cooking procedure at 100 °C. After the 
precipitation of plasma proteins in the samples with methanol, the MDA-TBA-
adducts were separated with the HPLC (emission: 563 nm; exitation: 532 nm). 
This method refers to a publication by Banni, Lucchi et al. 1996 and Thomson 
and Smith, 1985.  
 
3.2.2 Chemicals, materials, apparatus 
Following chemicals were used for the assay: 
 
For the standards: 
o Tetraethoxypropan (TEP) (Sigma) 
o Ethanol 96% p.a. (Riedel de Haen) 
o Distilled Water  
o Phosphoric acid 0.44 mol/l: 3 ml concentrated ortho-phosphoric acid 
(density 1.71 g/ml; 85%) fill up to 100 ml with distilled water 
o Thiobarbituric acid (TBA) (Sigma): 0.6 g TBA dissolved in 100 ml distilled 
water 
o Methanol/Sodium Hydroxide (Riedel de Haen): 4.5 ml 1 molar sodium 
hydroxide dissolved in 50 ml methanol chromasolv 
o 1 N sodium hydroxide: 4 g caustic soda dissolved in 100 ml distilled 
water 
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For the eluent (mobile phase): 
o Phosphate buffer: 6.8 g potassium dihydrogen phosphate dissolved in 
800 ml distilled water; adjust the pH to 6.8; fill up to 1 l 
o Methanol chromasolv (Riedel de Haen) 
o Eluent’s composition: Phosphate : Methanol = 60:40 
 
The eluent has to be filtered through filter paper and degassed in an ultrasonic 
bath for 15 minutes.  
 
3.2.3 Standards preparation 
Step 1: 
50 µl of TEP (09%; density = 0,92 g/ml) dissolved in 50 ml ethanol : water (40 : 
60) 
 
Step 2: 
100 µl Standard 1 dissolved in 50 ml ethanol : water (40 : 60 - 8,12 µM) 
Standard 1: distilled water (0 µM) 
Standard 2: 100 µl of Standard 3 + 100 µl water (0,195 µM) 
Standard 3: 100 µl of base material 2 + 2 ml water 
Standard 4: 100 µl of base material 2 + 900 µl water 
Standard 5: 100 µl of base material 2 + 500 µl water 
Standard 6: 100 µl of base material 2 + 300 µl water 
Standard 7: 100 µl of base material 2 + 100 µl water 
Standard 8: 100 µl of base material 2 
 
3.2.4 Sample preparation 
700 µl phosphoric acid (44 mmol/l), 500 µl water and 50 µl of the standard 
plasma or distilled water and 250 µl TBA-solution were pipetted into a pyrex 
glass. The tubes were boiled for 60 minutes. After cooling down in ice water (for 
about 10 minutes), the samples were neutralized with methanol : sodium 
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hydroxide. The plasma proteins were denaturated by methanol, sodium 
hydroxide neutralized the phosphoric acid. Then 100 µl methanol/sodium 
hydroxide were pipetted into test tubes together with 100 µl of the standards or 
sample. Afterwards the samples were centrifuged for 2 minutes at 3000 rpm. 
The pH was checked with a pH indicator paper and adjusted to 7. 20 µl of each 
sample were injected. 
 
3.2.5 Instruments 
HPLC (Shimadzu)   LC-20AT Dual Reciprocating Plunger HPLC Pump 
Column:   Merck LichroCart 125-4 Lichrospher 100 RP-18 (5µm) 
Detector:   Hitachi Model F-1050 Fluorescence Spectrophotometer 
Integrator:  Hitachi model D-7500 
Autosampler: 2 trays; one for 8 standard samples and 70 for samples 
 
Assessment details 
Mobile phase: buffer : methanol (60 : 40) 
Flow rate:   1 ml/min 
Detetor settings: emission wave length: Em = 563 nm 
   excitation wave length: Ex  = 532 nm 
Sensitivity:  20 
 
3.2.6 Calculation 
A calibration line was calculated with the 8 standards (see above step 2). With 
the calibration line the concentration of the plasma samples was calculated 
using the linear regression formula (y=k*x+d), which was given in µmol MDA 
per ml plasma.  
 
3.2.7 Quality assurance 
A standard deviation and variation coefficient of a control plasma was detected 
(further a control plasma was used daily as an internal standard) (Tab. 5).  
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Tab. 5: Accuracy of MDA analysis 
 
A Correlation coeffiient and variation coefficient for the method quality was also 
calculated: 
r (standard): 0.997 
cv (sample): 7.6 % 
 
 
3.3 Ferric Reducing Ability of Plasma (FRAP) 
The FRAP-assay, which was developed by Benzie & Strain (1996), has been 
approved as a reliable method for measuring the antioxidant capacity of 
biological fluids. Its function is based on the principle of the reduction of Fe 3+ 
through antioxidant substances which causes a blue-colored Iron(II)-complex 
due to the Fe3+ / Fe2-Tripyridyltriazin(TPTZ)-redoxsystem. FRAP was measured 
spectrophotometrically at a low pH of 3,6. Fe2+ was detected at 593 nm Benzie 
& Strain, 1996. This method was adopted at our department earlier Valentini, 
2009 
 
 
 
 MDA (µmol/l) SD %CV 
Day 1 intraday 1.53 0.09 
 
6.3 
Day 2 intraday 1.23 0.12 
 
9.9 
Day 3 intraday 1.23 0.10 
 
7.9 
Day 4 intraday 1.26 0.04 
 
2.9 
Day 5 intraday 1.27 0.05 
 
3.9 
Interday 1.30 
 
0.13 
 
9.8 
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3.3.1. Chemicals 
Reagents    Chemical formula  Manufacturer 
  
Sodium acetate trihydrate  C2H3NaO2 * 3H2O  FlukaChemicals 
Acetic acid    C2H4O2    Fluka Chemicals 
2-amino-4,6-dichloro-s-triazine C18H12N6    Fluka Chemicals 
(TPTZ) 
Hydrochloric acid   HCl     Riedl-de Haen  
Iron (III) Chloride-hexahydrat FeCl3 *  6 H2O   Riedl-de Haen 
Ferrous II sulphate heptahydrate  FeSO4 * 7 H2O   Fluka Chemicals  
 
3.3.2. Standards and antioxidants 
The standard curve was prepared with a Fe2+-solvent with known 
concentrations in the range of 50 to 1000 µmol/l (1000, 750, 625, 500, 250, 125, 
50 µmol/l). The antioxidative capacity of the plasma sample was analyzed on 
the basis of the standard curve. Trolox (Sigma Chemicals, USA) in aqueous 
solution was used as a control substance. 
 
3.3.3. Instruments and settings 
The absorbance was carried out with a microplate reader from BMG Lab-
technologies (Germany). The instruments temperature was set to 37 C, which 
was maintained throughout the analysis. The absorbance filter was set with an 
excitation wave length of 540 nm. The data were processed with the FLUOstar 
Optima Software Version 1.20-0. The reagents were pipetted with an 
Eppendorf-pipette into uncoated 96-well microplates. 
 
Main settings of FLUOstar Optima Software 
 
Assay name      Frap 
Used microplate      96-well microplates 
Measuring method     Absorption 
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Wave-length      540 nm 
Temperature      37 C 
Start of measuring     1 s  
Number of measurements    10 
Interval between measurements   36 s 
Mix       5 s before the first cycle 
 
3.3.4. Preparing the solvents 
 
Acetate buffer (300 mmol/l); pH 3.6: 
3.1 g C2H3NaO2 * 3 H2O and 16 ml concentrated acetic acid were dissolved in 1 
l distilled water. 
 
TPTZ-solution (10 mmol/l in 40 mmol/l HCL): 
31.2 mg 2.4.6-Tripyridyl-s-triazin and 585 µl HCl were dissolved in 100 ml 
distilled water. 
 
FeCl3 * 6 H2O-solution (20 mmol/l): 
54.1 mg Iron (III)-chloride dissolved in 100 ml distilled water. 
 
Frap-solution: 
25 ml acetate buffer was mixed with 2,5 ml Iron (III)-chloride and 2,5 ml TPTZ-
solution (10:1:1). The solution was freshly prepared every day and kept in a 
water bath with 37 C.  
 
FeSO4 * 7 H2O-solution (2000 mmol/l): 
55,6 mg Iron (II)-sulfate was dissolved in 100 ml distilled water. The Iron(II)-
sulfate-stock-solution was diluted with distilled water to the concentrations of 
1000, 750, 625, 500, 250, 125, 50 µmol/l. 
 
Trolox-solution: 
18 mg Trolox (Aldrich) were weighed into a 25 ml volumetric flask and filled up 
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with phophate buffer. The Trolox-solution was kept in an ultrasonic bath for 8 
hours. The trolox was pipetted into 1 ml cups and stored at -20 C.  
A trolox-dilution series was made daily at the concentrations 50, 100, 200, 300, 
400, 550 and to 700 µmol/l.  
 
3.3.5 General application 
First 30 µl of destilled water were pipetted into all wells; apart of the blank, 
where 40 µl distilled water were used. Then 10 µl plasma were pipetted into the 
wells of the microplate. Finally, 300 µl Frap-solution were added into all wells. 
The Frap-solution was preheated to 37 C in a water bath (Tab. 6 and 7). It was 
taken care that the time between pipetting the Frap-solution and starting the 
measurement was shorter than 1 minute. Ideally the time for all the plasma 
samples should be approximately the same. 
 
 
all in µl Standard Blank Control (Trolox) Sample 
Iron(II)-solvent 10 - - - 
Trolox - - 10 - 
Heparin-plasma - - - 10 
Acqua distilled 30 40 30 30 
Frap-reagent 300 300 300 300 
  
Tab. 6: Pipetting schema for the 96-well microplates (FRAP assay) 
 
The microplate reader is adjusted to shake for 5 seconds before the start of the 
assay and then on an interval of 36 seconds for 6 minutes in total. The final 
value, which has to be applied against the blank value (40 µl water and 300 µl 
Frap-solvent), was obtained after 6 minutes. For the quantification of the 
concentrations (which means antioxidative capacity) an Iron(II)-standard series 
was used (Fig. 6), which was pipetted with samples, Trolox and blanks. The 
Trolox-solution (50 – 700 µmol/l) was used as a control (Fig. 7).  
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3.3.7 Evaluation 
A standard curve was calculated out of the difference between the absorption of 
the standard solvent Iron (II) (50, 125, 250, 500, 625, 750, 1000 µmol/l) and the 
absorption of the blank. The absorption of the blank was also substracted from 
the absorption of the plasma. The concentration (µmol/l) of the plasma sample 
was calculated using the linear regression formula (y=k*x+d) (Fig. 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Illustration of the Iron (II)-standard curve 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Illustration of Trolox-curve 
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Plate 1 
  
 
 
Plate 2 
 
 
Tab. 7: Microplate (FRAP assay) 
Fe2+ for Iron(II)-solvent, K for control; S for plasma sample; B for blank; T for Trolox. 
 
 
 
 
 
 
 1 2 4 4 5 6 7 8 9 10 11 12 
A Fe2+ Fe2+ C C S1_0 S1_0 S3_0 S3_0 S5_0 S5_0 S7_0 S7_0 
B Fe2+ Fe2+ C C S1_1 S1_1 S3_1 S3_1 S5_1 S5_1 S7_1 S7_1 
C Fe2+ F2+ C C S1_2 S1_2 S3_2 S3_2 S5_2 S5_2 S7_2 S7_2 
D Fe2+ Fe2+ C C S1_3 S1_3 S3_3 S3_3 S5_3 S5_3 S7_3 S7_3 
E Fe2+ Fe2+ C C S2_0 S2_0 S4_0 S4_0 S6_0 S6_0 S8_0 S8_0 
F Fe2+ Fe2+ C C S2_1 S2_1 S4_1 S4_1 S6_1 S6_1 S8_1 S8_1 
G Fe2+ Fe2+ C C S2_2 S2_2 S4_2 S4_2 S6_2 S6_2 S8_2 S8_2 
H   C C S2_3 S2_3 S4_3 S4_3 S6_3 S6_3 S8_3 S8_3 
 1 2 4 4 5 6 7 8 9 10 11 12 
A T T B B S9_0 S9_0 S12_0 S12_0 S14_0 S16_0 S18_0 S20_0 
B T T B B S10_1 S10_1 S12_1 S12_1 S14_1 S16_1 S18_1 S20_1 
C T T B B S10_2 S10_2 S12_2 S12_2 S14_2 S16_2 S18_2 S20_2 
D T T B B S10_3 S10_3 S12_3 S12_3 S14_3 S16_3 S18_3 S20_3 
E T T B B S11_0 S11_0 S13_0 S13_0 S15_0 S17_0 S19_0 S21_0 
F T T B B S11_1 S11_1 S13_1 S13_1 S15_1 S17_1 S19_1 S21_1 
G T T B B S11_2 S11_2 S13_2 S13_2 S15_2 S17_2 S19_2 S21_2 
H   B B S11_3 S11_3 S13_3 S13_3 S15_3 S17_3 S19_3 S21_3 
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3.3.8 Quality assurance 
Control plasma was determined tenfold within a day. Trolox was determined 
twofold for the 3 analyzing days. Standard deviation and the coefficient of 
variation are given for intra- and interday of control plasma and Trolox (Tab. 8).  
 
 
 n  (µmol/l) SD % VC 
Intraday 
(Control plasma) 10 279.02 11.52 4.13 
Day 1 (Trolox) 2 1 256.33 51.27 4.08 
Day 2 (Trolox) 2 1 238.02 7.16 0.58 
Day 3 (Trolox) 2 1 041.31 73.96 7.10 
Interday  2 1 178.55 119.21 10.11 
 
 
Tab. 8: Accuracy of the FRAP analyzing 
 
 
3.4 ORAC assay (Oxygen Radical Absorbance Capacity) 
Glazer 1990 and Ghiselli et al. 1995 have established the Orac assay, which 
was updated and improved by Cao et al. 1993. Over the years the method has 
been modified and updated many times. A major modification has been realized 
by Ou et al. 2001 using fluorescein as the fluorescent assay instead of B-
phycoerythrin (a protein segregated from Porphyridium cruentum), because 
fluorescein is superior. B-phycoerythrin was exchanged due to its inconsistency 
from lot to lot which led to varying reactivity of the peroxyl radicals. Fluorescein 
is photostable and preferentially used for the Orac assay Ou et al., 2001. 
Primarily, the Orac-assay was a time consuming method with a small sample 
output. Huang et al. 2008b therefore improved the method to high-output, 
which was fully automated in the assay procedure with a robotic eight-channel 
liquid handling system and a microplate fluorescence reader in a 96-well format. 
Later the system has been adjusted to the ability of defining the lipophilic, 
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hydrophilic and total antioxidant capacity of a medium Huang et al., 2002a. 
Prior et al. 2003 extracted and analysed hydrophilic and lipophylic antioxidants 
with a modified Orac-method, where they measured the “total antioxidant 
capacity” in protein free plasma. AAPH (2,2`-azobis 2-amidinopropane 
dihydrochloride) was applied as a peroxyl radical generator. The Orac assay is 
an effective and approved method for the determination of antixodative 
capacitiy, which is used in various fields as nutraceutical, pharmaceutical and 
food industries.  
 
 
3.4.1 Principle of the Orac assay 
The Orac assay is based on the oxygen radical absorbance capacity where a 
peroxyl radical (AAPH) oxidizes fluorescein in competition with an antioxidant 
(in the plasma sample) (Huang et al., 2005).  At a temperature of 37 °C and a 
pH at 7.4 the AAPH leads to ROO  -production, which reacts with the 
fluorescein. This results in a gradual loss of fluorescence intensity. Antioxidants, 
which are in a plasma sample, inhibit the reaction between ROO  -and the 
fluorescent probe, which slows down or inhibits the fluorescence degradation. 
The Orac assay indicates the antioxidant potential of a plasma sample by using 
the area under the curve (AUC) in combination with inhibition time and inhibition 
potency Bispy et al., 2008. The principle of the Orac assay is illustrated in Fig. 
9. 
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Fig. 7: Principle of the Orac assay, Huang et al., 2002b 
 
Our analysis was based on the Orac assay adopted to the FLUOstar Optima, a 
microplate fluorescence reader with a 96 well microplate. This method was 
adopted at our department earlier Stadlmayer, 2009. We have used an AAPH 
amount of 426.42 mg and 5 ml of buffer solution, which was exactly half of the 
amount given in the instructions of previous thesis Stadlmayer, 2009. Further 
we have chosen a plasma dilution factor of 1:160 instead of 1:620. 
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3.4.2 Chemicals, materials, apparatus 
 
Following chemicals have been used for the assay: 
 
Reagents Chemical 
Formula 
Manufacturer 
AAPH  
2,2`-azobis(2-amidinopropane) 
dihydrochloride 
C8H18N6 · 2 HCl Aldrich (Germany)
Disodium Fluorescein C20H10Na2O5 Fluka Chemica (CH)
Phosphate buffer (pH 7.4) NA2HPO4 + 
KH2PO4 
Fluka Chemica (CH)
Trolox (standards) C14H18O4  
 
Apparatus 
o FLUOstar Optima FL 600 Microplate Fluorescence Reader  (Bio-Tek 
Instruments) 
o 96-well polystyrene microplates (dark) 
o Water bath (37 °C) 
o Vortex mixer 
o Electrical pipettes 
 
FLUOstar Optima is an automated microplate multidetection reader for 
measuring 4 different types: 
 
o Fluorescence Intensity  
o Time-Resolved Fluorescence  
o High-Performance Luminescence  
o Absorbance - UV/Vis  
 
For the Orac assay we used the Fluorescence adapter. Before starting the 
analysis it had to be ensured that the right adapter was used. Furthermore the 
basic settings and the reader configurations were adjusted to fluorescence. 
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3.4.2.1 Basic instrument settings 
 
Test name      Orac 
Mode       Fluorescence, Plate Mode 
Microplate      Sterlin 96 
No of cycle      35 
No of flashes per well and cycle   10 
Cycle time      60 s 
Filter and Integration    Excitation filter: 485 nm 
       Emission flilter: 520 nm 
Temperature Control    37 °C 
Shaking options     orbital, 1s, before first cycle 
Gain       adjusted automatically 
 
 
3.4.2.2 Reagent, standard and sample preparation 
Phosphate buffer 75 mmol/l, pH 7.4:  
10.96 g Na2HPO4 + 10.21 g KH2PO4 were dissolved in 1 liter distilled water. pH 
was adjusted to 7.4 with KOH. It was important to keep the pH milieu of 7.4 as 
fluorescein is only working at this pH.  
 
AAPH (97%): 
426.42 mg AAPH was dissolved in 5 ml preheated phosphate buffer to the 
concentration of 315 mmol/l. Due to the sensitivity of the level of peroxyl radical 
generation in AAPH, the optimal timing of preparation and correct handling was 
important. Therefore the solution was made right before the analysis (less than 
1.30 min preferably).  
 
Fluorescein disodium stock solution: 
0.158 mg fluorescein disodium was dissolved in 100 ml phosphate buffer to the 
concentration of 4.19*10-3 mmol/l. Under dark and cold conditions (4 °C) one 
can keep it for 1-2 months. 
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Fluorescein disodium working solution: 
The working solution was prepared daily. 487.5µl of fluorescein disodium stock 
solution were dissolved in 25 ml phosphate buffer. The final concentration was 
8.16*10-5 mmol/l.  
 
Standard (Trolox ): 
62.58 mg Trolox was diluted in 100 ml phosphate buffer for a concentration of 
2.500 µmol/l and put in an ultrasonic bath for complete dissolving. The Trolox 
stock solution was filled in cups and kept frozen until use. A daily standard 
curve was diluted to the following concentrations: 100, 75, 50, 12,5 and 6,25 
µmol/l.  
 
Control (reference plasma): 
Reference plasma was diluted carefully with phosphate buffer with the dilution 
factor of 1:160.  
 
Sample (plasma): 
Plasma was also diluted with phosphate buffer (dilution factor of 1:160). Due to 
the high dilution factor of the plasma, the samples were vortexed properly. 
 
 
Reagents/wells Blank (µl) Control (µl) Standard (µl) Sample (µ) 
Phosphate buffer 25 - - - 
Trolox - - 25 - 
Reference plasma - 25 - - 
Plasma sample - - - 25 
Fluorescein solution 150 150 150 150 
Incubation of the microplate: 10 min with 37 °C in FLUOstar Optima 
AAPH solution (37 °C) 25 25 25 25 
 
Tab. 9: Pipetting schema of the ORAC assay 
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3.4.3 Implementation 
The FLUOstar Optima plate reader was activated and set to the temperature of 
37 °C. The reagents and samples had to be prepared as described before. 
Fluorescein working solution was prepared daily and kept in a dark flask. 5 ml 
phosphate buffer were placed in the water bath (37 °C), in which AAPH was 
dissolved. Further Trolox had to be diluted to the standing concentrations 
defined below. Also the plasma samples were diluted with phosphate buffer  
(1:160) in test tubes (10 µl plasma + 1.6 ml phosphate buffer). As the samples 
were highly diluted, careful shaking was of importance. When all reagents are 
prepared and the instrument adjusted, the plates were pipetted according to the 
pipetting scheme. 25 µl of sample/blank/trolox were pipetted into the wells. 
Samples and Trolox were analyzed in dublicates. Afterwards, 150 µl of 
fluorescein solution were transferred in each well and immediately incubated in 
the FLUOstar Optima for 10 minutes. A special test program was adopted for 
incubation without measuring. Shortly after the incubation, AAPH was dissolved 
in 5 ml preheated phosphate buffer so that 25 µl of that solution could be 
transferred to each well. Immediately after this step, the fluorescence was 
measured for 35 minutes under the required and already mentioned conditions 
(pH 7.4 and 37 °C) (Tab. 9). The evaluation software safed all the data 
throughout the 35 minutes, which was later compared to the Trolox (standard), 
and expressed as µmol of Trolox equivalents TE/l. The calculation of the final 
data is given in part 3.4.4. 
 
3.4.3.1 Distributing schema of samples on the microplate 
As the analyzing time was 35 minutes, 6 columns could be filled per run. 
Therefore it is required to work with two plates. While the first plate was 
measured, the second could be prepared (Tab. 10).  
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Plate 1 
 
 
 
 
 
 
 
 
 
Plate 2 
Tab. 10: Microplates of the ORAC assay 
 
B...Blank; C...Control (reference plasma); T...Trolox; S...Sample  
 
3.4.4 Data evaluation 
The formula for the area under the curve was applied to a Microsoft Excel sheet 
and the data was calculated. The AUC of the blank was subtracted from the 
AUC of the sample to obtain the Net AUC (Fig. 10) [OU et al., 2001]. 
 
1. Evaluation of AUC (area under the curve) and Net AUC for samples (plasma) 
and standard (Trolox): 
 
  1 2 3 4 5 6 
A B 1 T (12,5 µmol) S 1 S 5 S 9 S 13 
B B 1 T (12,5 µmol) S 1 S 5 S 9 S 13 
C C 1 T (  50 µmol) S 2 S 6 S 10 S 14 
D C 1 T (  50 µmol) S 2 S 6 S 10 S 14 
E C 2 T (  75 µmol) S 3 S 7 S 11 S 15 
F C 2 T (  75 µmol) S 3 S 7 S 11 S 15 
G T(6,25µmol) T ( 100 µmol) S 4 S 8 S 12 S 16 
H T(6,25µmol) T ( 100 µmol) S 4 S 8 S 12 S 16 
  7 8 9 10 11 12 
A B 1 T (12,5 µmol) S 17 S 22 S 26 S 30 
B B 1 T (12,5 µmol) S 18 S 22 S 26 S 30 
C C 1 T (  50 µmol) S 19 S 23 S 27 S 31 
D C 1 T (  50 µmol) S 19 S 23 S 27 S 31 
E C 2 T (  75 µmol) S 20 S 24 S 28 S 32 
F C 2 T (  75 µmol) S 20 S 24 S 28 S 32 
G T(6,25µmol) T ( 100 µmol) S 21 S 25 S 29 S 33 
H T(6,25µmol) T ( 100 µmol) S 21 S 25 S 29 S 33 
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AUC = 0.5 + f1/f0 + …fi/f0 + …f34/f0 + 0.5 (f35/f0) 
f0 = initial fluorescence reading at 0 min; fi  = fluorescence measure at time i. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Illustration of Net AUC (= AUC of Antioxidant – AUC of blank) 
 
2. Standard curve 
The standard curve was obtained by plotting the 4 concentrations of Trolox 
against the corresponding Net AUC (Fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Linear plot of Trolox concentrations against the Net AUC. 
3. Calculation of ORAC values via Trolox regression equation 
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The relative ORAC value (Trolox equivalents) was calculated and expressed as 
µmol Trolox equivalent/l and the dilution factor of the plasma (1:160) was 
considered. 
 
3.4.4.1 Quality assurance 
Reference plasma was determined twofold over 5 days. In tab. 11 the standard 
deviation SD and the coefficient of variation is given for intra- and interday (Tab. 
11).  
 
 ORAC (µmolTE/l) SD %CV 
Day 1 intraday 7 132.1 259.3 
 
3.7 
Day 2 intraday 8 835.9 322.4 
 
3.6 
Day 3 intraday 7 767.8 341.7 
 
4.4 
Day 4 intraday 8 082.3 73.1 
 
0.9 
Day 5 intraday 8 313.4 292.6 
 
3.5 
Interday 8 026.3 
 
633.9 
 
7.9 
 
 
Tab. 11: Accuracy of the ORAC assay  
 
 
3.5 Statistical evaluation 
Statistical analysis was performed with SPSS for Mac (17.0 MacOsMl). Data 
are presented as mean  SD. Kolmogorov-Smirnov test has been applied to 
determine normal distribution. One way ANOVA and unpaired t-test were used 
to evaluate baseline data. Further an analysis of variance with repeated 
measurement has been applied to investigate significant effects of the 
intervention. Significant differences are given as *p < 0,05. 
 
 
4. Results and discussion 
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4.1 Malondialdehyde 
Differences between the health groups 
The MDA levels did not show any significant differences between the four 
health groups at baseline. The mean values were as follows: IDDM (1.22  0.29 
µmol/l); NIDDM (1.21  0.32 µmol/l); healthy (1.34  0.43 µmol/l); IFG (1.35  
0.29 µmol/l). The intervention group showed similarly to the information group 
no significant differences in the levels of MDA between the 4 health groups at 
baseline (T_0). The levels in the IFG and healthy group were slightly higher 
than in IDDM- and NIDDM-subjects at baseline. Further, there were no 
significant differences in the MDA levels between the information and 
intervention group at baseline.  
 
Gender differences 
No significant differences could be found between males and females in MDA 
levels at baseline. The female group showed only slightly higher levels (males: 
1.20  0.27 µmol/l; females: 1.27  0.35 µmol/l).  
 
Changes during the intervention 
During the study the levels in the information group (Fig. 12) did not change 
significantly. The healthy group showed a decrease in MDA levels (- 19.5 %) 
between the levels at baseline (T_0) and after the period of 8 weeks (T_2). The 
levels declined further and the difference between baseline (T_0) and the last 
timepoint (T_3) accounted for – 26 %. In the intervention group (Fig. 13) there 
was no change in the four health groups between T_0 and T_2. A slight 
decrease was detected in IFG (- 4.4 %) and in the healthy group (- 3.7%) 
between baseline and after 8 weeks of intervention. Further, the IFG group 
showed a decrease (- 10 %) in MDA between T_0 and T_3. However, these 
differences are not statistically significant.  
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Fig. 10: MDA-levels (µmol/l) in the information group in the four different health groups 
at 3 different time points T_0 (at baseline), T_1 (after 4 weeks) and T_2 (after 8 weeks 
of study)  
 
 
Fig. 11: MDA levels (µmol/l) in the intervention group in the four different health groups 
at 3 different time points T_0 (at baseline), T_1 (after 4 weeks of intervention) and T_2 
(after 8 weeks of intervention)  
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4.1.1 Discussion  
In the whole groups the average MDA level was 1.23  0.33 µmol/l. The 
minimum concentration amounted to 0.56 µmol/l and the maximum to 2.12 
µmol/l. Comparing the 4 different health groups no significant differences in 
minimum and maximum levels were observed (IDDM minimum 0.61 µmol/l, 
maximum 2.02 µmol/l; NIDDM 0.56 µmol/l vs. 1.99 µmol/l; healthy 0.69 µmol/l 
vs. 1.86 µmol/l and IFG 0.92 µmol/l vs. 1.87 µmol/l). The average MDA levels in 
healthy subjects ranged from 0.36 to 1.24 µmol/l. However, the average MDA 
levels in healthy humans are quite contradictory and many different levels have 
been indicated in scientific publications. Depending on the methods used 
(UPLC, HPLC, LC-MS), levels have been detected between 0.1 and 15 µmol/l 
(Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 12, 2008). 
Almost every lab has its own procedure regarding the used reagents, incubation 
time and temperatures. Due to the same procedures our results agree with 
Nielsen et al. (1997), who indicated MDA levels between 0.36 and 1.24 µmol/l in 
plasma samples of healthy subjects. However, contradictory results in literature 
do exist about serum MDA concentrations in patients with diabetes. Bates et al. 
(1997) reported similar MDA levels in diabetic subjects compared to healthy 
subjects. Pasaoglu et al. (2004) detected significantly increased MDA levels 
both in serum and erythrocyte in diabetes patients compared to a healthy 
control group. According to their study the diabetes-induced oxidative 
impairment is more distinct in red blood cells compared to other tissues. The 
reasons are high concentration of iron and polyunsaturated fatty acids in the red 
cells. Further they serve as an oxygen transporter and play a protective role of 
the host in vivo by neutralizing exogenous and endogenous free radicals. This 
could be a reason why MDA levels differed only marginally when comparing the 
4 different health groups, as in our study MDA was analyzed in the subject’s 
plasma.  
Åsgård et al. (2007) investigated whether fruit and vegetable consumption, 
dietary antioxidants and plasma antioxidant concentrations are associated with 
oxidative stress in type 2 diabetic patients. They concluded that a negative 
correlation between fruit and vegetable consumption with markers of oxidative 
stress exists. Among these markers they reported that Vitamin E correlated 
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negatively with MDA levels (r = - 0.287). Certainly a one to one conferment of 
the mentioned study cannot be done with our study but it supports the 
hypothesis that fruit and vegetables have positive effects on biomarkers of 
oxidative stress in diabetic type 2 patients. However, in our study the 
consumption of the plant oil rich in polyunsaturated fatty acids (PUFA) has to be 
considered as an additional influencing factor since PUFA are susceptible to 
oxidation, which could have effects on MDA as mentioned above.  
Armstrong et al. (1996) assessed the influence of a dietary treatment, which 
was high in antioxidants and vitamins in NIDDM-subjects on the antioxidant 
status and lipid peroxidation. Their study revealed that the MDA levels 
decreased significantly after the diet. Further the MDA levels in the diabetes 
group at baseline were significantly lower than in the control group.  
However, regarding our study, the MDA levels did not differ significantly 
between the 4 health groups. Further they reported a weak correlation between 
MDA and HbA1c, which was also detected in our findings.  
As already mentioned, healthy subjects had MDA-levels between 0.36 and 1.24 
µmol/l. In our study, at baseline 52.5 % of all participants showed MDA levels  
1.24 µmol/l. After 8 weeks of intervention at T_2 56.7 % of all participants had 
MDA levels  1.24 µmol/l. So there has been a slight increase in the MDA levels 
when comparing values at baseline (T_0) and after 8 weeks of intervention 
(T_2). However, when comparing (T_0) with (T_3) around 70 % of all subjects 
showed levels  1.24 µmol/l and only 29.3 % had levels ≤ 1.24 µmol/l. During 
the intervention 25 ml of plant oil were given to the participants. There might be 
an association between oil intake and higher levels of MDA, as the oil was rich 
in polyunsaturated fatty acids that might have been oxidized in the course of the 
metabolism and led to a possible increase in MDA levels. Södergren et al. 
(2001) investigated the effects of a daily consumption of a rapeseed oil based 
diet (9.2 g PUFA) with easily oxidized polyunsaturated fatty acids such as 
alpha-linolenic acid compared to a control diet high in saturated fatty acids (1.1 
g) on lipid peroxidation for 4 weeks. They showed no increase in lipid 
peroxidation, measured as MDA in plasma, compared to the saturated fat 
group. The reason might be the amount of antioxidants in the oil, which may 
inhibit the oxidation of the unsaturated fatty acids. As the MDA levels in the 
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present study almost remained unchanged despite of the relatively high amount 
of the oil, it is in accordance with the results of Södergren et al. (2001). Another 
reason why the MDA levels in the present study remained unchanged may be 
the considerable amount of vegetables, which contain antioxidants. 
Kesavulu et al. (2004) showed increased MDA levels in type 2 diabetic subjects 
and even higher levels in diabetics with microvascular complications. They also 
suggested that hyperglycemia is linked with hyperlipidemia, which is often found 
in diabetic subjects. These might be causative factors for the elevated 
generation of oxygen free radicals and lipid peroxides. The authors reported a 
positive correlation of MDA with HbA1c and cholesterol. However, we could not 
find a correlation between MDA and HbA1c or cholesterol in our subjects. Our 
findings are in accordance with Gallou et al. (1993) and Akkus et al. (1996) who 
didn’t find a link between MDA levels and HbA1c in diabetic subjects.  
As Vitamin E is a hydrophobic antioxidant occurring in lipoproteins and 
membranes, and considered as the most important scavenger of lipid peroxyl 
radicals, it is reported to show a positive correlation with MDA. Further HDL is 
positively correlated with MDA (Lodovici et al., 2004). They suggested the 
existence of a remaining adaptive response of HDL, even if it is not sufficient to 
prevent lipid peroxidation. This circumstance may indicate that HDL and Vitamin 
E play a role in the compensatory response to hyperglycemia-induced oxidative 
stress (Meydani et al., 2004). In their study they hypothesized that Vitamin E 
might be involved in the regulation of plasma HDL as it is reported for LDL. 
However, a positive correlation of MDA with HDL and Vitamin E could not be 
detected in our study.  
According to Soliman et al. (2008), there is a significant positive correlation 
between SOD and MDA in both NIDDM- and healthy subjects. They reported of 
increased MDA and SOD levels in diabetic patients, being exposed to an 
elevated oxidative stress. On the other hand they found declined concentrations 
of glutathione referring to a lowered scavenging ability of glutathione-dependent 
anti-oxidant defensive system contrary to enhanced lipid peroxidation 
processes in these subjects.  
However, the studies on the status of antioxidants and antioxidant enzymes in 
diabetic patients are quite contradictory, both enhanced and declined 
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antioxidant activities have been reported [Kaji et al., 1995; Kesavulu et al., 
2000]. In our study, a correlation between SOD and MDA was not found. 
 
 
4.2 Ferric Reducing Ability of Plasma 
 
Differences between the health groups 
The FRAP levels showed no significant differences when comparing the four 
different health groups at baseline (IDDM 340  67.72 µmol/l; NIDDM 335.1  
73.70 µmol/l; healthy 368.6  63.91 µmol/l; IFG 362.3  71.31 µmol/l). The 
FRAP levels in the IDDM- (- 7.75 %) and NIDDM-subjects (- 9.1 %) were not 
significantly lower compared to the healthy group. Interestingly, the IFG group 
had almost the same levels as the healthy group. Further, the differences in the 
FRAP levels between information and intervention group were not significantly 
different. However, a slight not significant difference was detected in the 
intervention group (351.3  69.50 µmol/l) (+ 7.1 %) compared to the information 
group (327.9  70.28 µmol/l) at baseline (T_0). 
 
Gender differences 
At baseline the FRAP levels showed a slight difference (4.7 %) between male 
and female (353.8  71.26 µmol/l vs. 337.0  69.28 µmol/l). The differences 
were not significant.  
 
Changes during the intervention 
In the course of the study the information group (Fig. 14) showed no significant 
changes in the FRAP levels between T_0 (baseline) and T_2 (after 8 weeks of 
intervention).  
However, when the information group was divided into four groups according to 
their state of health, a significant increase in the FRAP values could be detected 
for the time effect in the healthy group (p = 0.032). 
In the intervention group (Fig. 15) a significant increase in the FRAP levels 
could be detected during the intervention. FRAP values (T_0 – T_1 p = 0.017) 
increased by 6.5 % after 4 weeks of intervention and remained at that level at 
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T_2 (T_0 – T_2 p = 0.031).  
When the intervention group was divided into four groups according to their 
state of health, there was a significant change in the IDDM (p= 0.004;  
T_0 – T_1 p = 0.004) (Fig. 13) and in the healthy group for the time effect  
(p = 0.047). The levels of FRAP after the return to the usual diet (T_3) remained 
(p = 0.004) higher than at baseline (T_0). 
 
  
 
 
Fig. 12: Information group: FRAP levels at the 3 different time points T_0 (at baseline), 
T_1 (after 4 weeks of intervention), T_2 (after 8 weeks of intervention) in the four 
different health groups 
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Fig. 13: Intervention group: FRAP levels at the 3 different time points T_0 (at baseline), 
T_1 (after 4 weeks of intervention), T_2 (after 8 weeks of intervention) in the four 
different health groups 
* significantly different from T_0  
 
4.2.1 Discussion  
 
At baseline (T_0) the average FRAP level was 343.1  70.24 µmol/l. The lowest 
level amounted to 149.4 µmol/l and the maximum to 567.5 µmol/l. When the 
information group was divided into four groups according to their state of health, 
the healthy group showed a significant increase in FRAP levels. In the 
intervention group the IDDM and the healthy subjects showed significantly 
increased levels. 
Lodovici et al. (2004) reported lower FRAP levels in type 2 diabetes subjects 
when compared to healthy controls. Further, type 2 diabetic subjects with poor 
glycemic control had even lower levels, notably those with complications the 
lowest.  
Roussel et al. (2008) investigated the antioxidantive effect of 250 mg of dried 
cinnamon extract given twice a day in patients with impaired fasting glucose for 
a period of 12 weeks compared to a placebo group. FRAP values increased in 
the cinnamon group, unlikely in the placebo group, where the values didn’t 
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change. Bub et al. (2008) examined the influence of a moderate intervention 
with carotenoid-rich vegetable products on the lipid peroxidation and antioxidant 
status in 25 healthy men. The intervention period lasted 8 weeks. In the first 2 
weeks the participants received a diet low in carotenoids followed by a 2 week 
period with 330 ml tomato juice per day. For the following 2 weeks the 
participants received 330 ml carrot juice and finally 10 g spinach powder for the 
last two weeks. The intervention resulted in significantly reduced plasma 
thiobarbituric acid reactive substances and reduced lipoprotein oxidizability 
resulting in an enhanced lag time of the tomato juice. Further, carrot juice and 
spinach powder showed no influence on lipid peroxidation. FRAP values, water-
soluble antioxidants, glutathione peroxidase and reductase activities however, 
did not change during any study period. In the present study, the FRAP values 
increased in the course of the intervention and the MDA levels did not change 
significantly. The participants in the present study consumed a large variety of 
vegetables, and possibly a mix of different kinds of vegetables may be more 
effective due to synergistic effects when compared to a single vegetable intake.   
 
 
4.3 Oxygen Radical Absorbance Capacity 
 
Differences in the health groups 
The ORAC levels did not differ significantly between the four different health 
groups at baseline (T_0) (IDDM 7 813  1 000 µmol/l; NIDDM 7 642  988.8 
µmol/l; healthy 7 649  947.9 µmol/l; IFG 7 571  1 029 µmol/l). Interestingly, 
the IDDM subjects had slightly higher ORAC values compared to the healthy     
(+ 2.1 %) or to the NIDDM group (+ 2.2 %). The lowest ORAC values at 
baseline were detected in the IFG group. Comparing the information and 
intervention group, a significant difference was detected at baseline (T_0) 
(information group 7 357  906.4 µmol/l vs. intervention group 8 751  983 
µmol/l).  
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Gender differences 
At baseline the ORAC levels did not differ significantly between males and 
females. However, it is interesting that males had higher values (+ 4 %) than 
females (male 7 883  1 003 µmol/l vs. female 7 565  954.4 µmol/l).   
 
Changes during the intervention 
In total, the information group (Fig. 16) showed significant changes in the 
ORAC values after 8 weeks (p = 0.003). From T_0 to T_1 the values were 
increased too, but not significantly (p = 0.065). At T_3 ORAC remained higher 
than at T_0 and the difference was statistically significant (0.039). In total, the 
ORAC values in the intervention group (Fig. 17) changed significantly both 
from T_0 to T_1 (p = 0.000) and T_0 to T_2 (p = 0.000). The ORAC values did 
not change significantly between T_1 and T_2. The ORAC values after return to 
the usual diet (T_3) were higher than the levels at baseline (+ 4.8 %) but were 
not significantly different.  
When the intervention group was divided into four groups according to their 
state of health, the ORAC levels increased significantly in all four health groups 
as follows:  
IDDM T_0 – T_2 (p = 0.006); NIDDM T_0 – T_1 (p = 0.003) and from T_0 – T_2 
(p = 0.012); healthy T_0 – T2 (p = 0.027); IFG T_0 – T1 (p = 0.002) and from 
T_0 to T_2 (p = 0.000) (Fig. 15)  
 
 
  
66
Fig. 14: Information group: ORAC levels at the 3 different time points T_0 (at baseline), 
T_1 (after 4 weeks of intervention), T_2 (after 8 weeks of intervention) in the four 
different health groups 
 
 
 
Fig. 15: Intervention group: ORAC levels at the 3 different time points T_0 (at baseline), 
T_1 (after 4 weeks of intervention), T_2 (after 8 weeks of intervention) in the four 
different health groups 
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4.3.1 Discussion  
At baseline the average ORAC levels amounted to 7 697  982.5 µmol/l, 
whereas the lowest detected level was 5 403 µmol/l and the highest 10 392 
µmol/l. The information group showed significant increased ORAC values after 
8 weeks of study. In the intervention group a significant increase was detected 
between baseline T_0 to T_1 and between T_0 and T_2. When the intervention 
group was divided into four groups according to their state of health, the ORAC 
levels increased significantly in all four health groups. 
Merzouk et al. (2004) investigated ORAC levels in diabetes (type 1 and 2) 
patients with and without complications compared to a healthy control group. 
The findings confirmed their suggestion that the scavenging capacity in plasma 
in diabetic subjects is lower than in controls, regardless of the type of diabetes 
and the existence of complications. Type 1 and type 2 diabetic subjects with 
complications showed lower ORAC values than those without. However, in their 
study all diabetic subjects were poorly controlled, having high glucose and 
HbA1c levels. They found an inverse correlation between HbA1c and ORAC. 
Merzouk et al. (2004) concluded that chronic hyperglycemia increases oxidative 
stress. In any case, according to the results of our study, a correlation could not 
be found between HbA1c and ORAC levels. A possible explanation is that 
diabetics who participated in this study were under medical control and did not 
have a poor glycemic control.  
Cao et al. (1998a) investigated the influence of a diet rich in fruit and vegetables 
on the antioxidant capacity in human plasma. In their study 36 healthy 
nonsmokers consumed a controlled diet consisting of 10 servings of fruit and 
vegetables per day for a period of 15 days or the same diet with an extra 2 
servings of broccoli a day on 6 to 10 days. This intervention resulted in 
significantly increased total antioxidant capacity analyzed with ORAC in both 
diets.  
In another short-term trial conducted by Cao et al. (1998b) the antioxidant 
capacity was investigated in 8 elderly women after intake of 240 g strawberries, 
294 g spinach or 300 ml red wine compared to a control meal or a vitamin C 
supplement of 1 250 mg. The antioxidant capacity in the serum, which was 
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measured with ORAC, increased significantly during the 4-h period after intake 
of strawberries, spinach or wine. The investigators suggested that the 
antioxidant phenolic composition in these foods was responsible for the 
enhanced serum antioxidant capacity, as it was associated with the noted 
elevations in the plasma levels of ascorbate (2-25 %) and urate (10-30 %).  
Also in the present study the ORAC levels have increased significantly during 
the intervention. The reason for this result is the high intake of vegetables and 
plant oil, which are rich in antioxidants. 
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5. Conclusion 
It has been reported that diabetic subjects have increased levels of oxidative 
stress, which is, on the one hand indicated as higher lipid peroxidation with its 
widely used marker MDA and lower antioxidative capacity. The “Diaplant” study 
investigated the influence of vegetable and plant oil intake on plasma MDA-
levels and the antioxidative capacity in type 2 diabetes mellitus subjects.  
MDA did not show any significant differences between the four health groups at 
baseline. In the whole study group the average MDA level was 1.23  0.33 
µmol/l. The minimum concentration amounted to 0.56 µmol/l and the maximum 
to 2.12 µmol/l. However, a slight, nonsignificant increase in MDA levels was 
detected when comparing T_0 (baseline) and T_2 (after 8 weeks of 
intervention). It can be suggested that the oil consumption played a role in the 
slightly increased MDA levels, as the polyunsaturated fatty acids in the oil were 
oxidized.   
The FRAP levels showed no significant differences when comparing the four 
different health groups at baseline. The average FRAP level was 344  70.24 
µmol/l at baseline. The lowest level amounted to 149.4 µmol/l and the highest to 
567.5 µmol/l. Slightly lower levels were determined in the IDDM (-7.75 %) and in 
the NIDDM (-9.1 %) when compared to the healthy control group.  
In total, the FRAP levels in the intervention group increased significantly  
(T_0 – T_1 p = 0.017) after 4 weeks of intervention and remained at that level at 
T_2 (T_0 – T_2 p = 0.031). Levels at T_3 (p = 0.004) were also significantly 
different from T_0 indicating, that the subjects kept their new eating behavior.  
In the intervention group the FRAP levels in the IDDM subjects showed a 
significant change (p= 0.004; T_0 – T_1 p = 0.004). Also in the healthy group a 
time effect (p = 0.047) was shown. ORAC levels did not differ significantly 
between the four health groups when compared at baseline. The average 
ORAC levels at baseline amounted to 7 697 µmol/l TE, whereas the lowest was 
5 403 µmol/l TE and the highest 10 392 µmol/l TE. In total, the information 
group showed significant changes in the ORAC values after 8 weeks (p = 
0.003) and also the intervention group both from T_0 to T_1 (p = 0.000) and 
T_0 to T_2 (p = 0.000). The ORAC levels in the intervention group increased 
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significantly in all four health groups as follows: IDDM T_0 – T_2 (p = 0.006); 
NIDDM T_0 – T_1 (p = 0.003) and from T_0 – T_2 (p = 0.012); healthy  
T_0 – T2 (p = 0.027); IFG T_0 – T1 (p = 0.002) and from T_0 to T_2  
(p = 0.000).  
In summary, it can be said that MDA did not decrease in the course of the 
study, however, it was also not significantly increased. This has been a positive 
outcome, as the subjects consumed a considerable additional amount of PUFA 
(LA 61.8 %; ALA 11.5 %) during the study. The antioxidative capacity increased 
significantly during the intervention and remained at that level until the end of 
the intervention. The main reason for the increase is the considerable amount of 
vegetable (300 g) and plant oil (25 ml) taken during the study, which are rich in 
antioxidants. 
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6. Summary 
According to the International Diabetes Federation 285 million people at the age 
of 20 to 79 are affected by diabetes worldwide. 439 million are expected to be 
diagnosed with diabetes in the year 2030. Type 2 diabetes mellitus and its late 
complications are linked to increased plasma lipid peroxidation with MDA as 
one marker and furthermore to decreased antioxidative capacity. A healthy diet 
plays an important role in both avoiding the onset and progress of late 
complications, once the disease is diagnosed. Therefore, an intervention study 
was conducted at the Department of Nutritional Sciences in Vienna to 
investigate the effect of a vegetable intake of 300 g in combination with 25 ml 
plant oil on the metabolism and oxidative stress parameters of type 2 diabetes 
subjects. The vegetables and plant oil were consumed daily in the course of the 
regular diet for the period of 8 weeks. 99 people participated in the trial, 
whereby 76 subjects (35 IDDM and 41 NIDDM) were diagnosed with diabetes, 
12 subjects had impaired fasting glucose levels (IFG) and 11 subjects were 
healthy. All participants were informed about a healthy diet and its beneficial 
effects at the beginning. The participants were randomly assigned to the 
information or intervention group. The subject’s blood was taken at baseline 
(T_0), after 4 weeks (T_1) and after 8 weeks (T_2) of intervention and further 
after return to the usual diet (+ 8 weeks) (T_3).  
MDA levels increased slightly, but not significantly in all four groups in the 
course of the study. The levels could have increased even more due to the 
considerable amount of plant oil rich in PUFA (LA 61.8 % of the total fatty acids; 
ALA 11.5 %), however this was prevented by the high amount of vitamin E (-
tocopherol 33 mg/100 g; -tocopherol 2.7 mg/100 g) in the plant oil and various 
antioxidants in the vegetables.  
The antioxidative capacity, which was measured by FRAP and ORAC, did 
increase significantly. In the intervention group the FRAP levels in the IDDM 
and the healthy subjects showed a significant increase.  
The ORAC values in the intervention group increased significantly in the NIDDM 
and IFG group after four weeks and in the IDDM, NIDDM, healthy and IFG 
group after eight weeks of intervention when compared to baseline.  
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It can be summarized that the intervention study increased the antioxidative 
capacity in type 2 diabetic subjects, mainly due to the high supply of antioxidant 
active compounds and did not change MDA levels although 25 ml of PUFA rich 
plant oil were consumed per day. 
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7. Zusammenfassung 
Laut der “International Diabetes Federation” leiden weltweit 285 Millionen 
Menschen im Alter von 20 bis 79 Jahren an Diabetes mellitus. Im Jahre 2030 
werden laut Schätzungen etwa 439 Millionen Menschen davon betroffen sein. 
Diabetes Typ 2 und seine Spätfolgen sind gekennzeichnet durch erhöhte 
Plasma-Lipidperoxidation und durch eine verminderte antioxidative Kapazität. 
Eine gesunde Ernährung kann vor der Entstehung und vor dem Fortschreiten 
von Diabetes-assoziierten Komplikationen schützen. Aus diesem Grund wurde 
eine Interventionsstudie am Department für Ernährungswissenschaften in Wien 
durchgeführt um den Effekt von 300 g Gemüse in Kombination mit 25 ml 
Pflanzenöl auf den Stoffwechsel und Parameter des oxidativen Stress von Typ 
2 Diabetikern zu untersuchen. Die Intervention dauerte 8 Wochen. In Summe 
nahmen 99 Personen an der Studie teil, von welchen 76 (35 IDDM und 41 
NIDDM) Diabetes hatten, 12 einen gestörten Nüchternblutzuckerspiegel 
aufwiesen und 11 gesund waren. Alle Studienteilnehmer wurden über den 
Einfluss einer gesunden Ernährung an Informationsabenden informiert und 
randomisiert der Informations- oder der Interventionsgruppe zugeteilt. An 4 
Terminen fand die Blutabnahme statt. Die Erste fand vor Beginn der 
Intervention (T_0) statt, die Zweite nach 4 Wochen (T_1) und die Dritte nach 8 
Wochen (T_2). Die letzte Blutabnahme (T_3) fand nach 16 Wochen (8 Wochen 
nach Ende der Intervention) statt.  
Die MDA-Konzentrationen stiegen leicht, aber nicht signifikant im Laufe der 
Studie in allen 4 Gruppen. Dies ist positiv zu beurteilen, da durch den hohen 
Konsum an Pflanzenöl reich an PUFA (LA 61.8 % an Gesamtfettsäuren; ALA 
11.5 %) auch ein starker Anstieg möglich gewesen wäre. Ein möglicher Grund 
für dieses Ergebnis ist vermutlich der hohe Anteil an Vitamin E im Pflanzenöl 
und der tägliche Verzehr von Gemüse, das reich an Antioxidantien ist.  
Die antioxidative Kapazität, welche mit den Methoden FRAP und ORAC 
bestimmt wurde, konnte durch die Intervention nach 4 Wochen signifikant 
gesteigert werden. Die Levels stiegen nach weiteren 4 Wochen der Intervention 
nicht weiter an, sondern blieben konstant. Ein wahrscheinlicher Grund für die 
signifikant erhöhte antioxidative Kapazität im Plasma der Typ 2 Patienten 
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könnte auch hier der relativ hohe Gemüseverzehr (reich an Antioxidantien) sein. 
Zusammenfassend kann bestätigt werden, dass ein täglicher Gemüse- und 
Pflanzenölverbrauch die antioxidative Kapazität im Plasma von Typ 2 
Diabetikern erhöht sowie die MDA-Konzentrationen nicht signifikant ändert.  
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8 Zusammenfassung Bosnisch 
 
Rezime 
 
Prema Federaciji međunarodnog diajabetesa, dijabetes imaju 285 miliona ljudi 
u starosti od 20 do 79 godina u cijelom svijetu. U 2030. godini procijenjuju se 
439 milona ljudi sa dijagnozom dijabetesa. Dijabetes 2 i njegove posledice su 
okarakterizovane povišenom koncentracijom lipidperoksidaza u plazmi, koje se 
uz pomoć MDA markera određuju, kao i smanjenom koncentracijom 
antioksidativnog kapaciteta. On se dokazuje uz pomoć FRAP i ORAC metoda. 
Zdrava ishrana štiti nastajanje i pojavu kasnijih posledica dijabetesa, ako je on 
već dijagnostikovan.  
Iz ovog razloga sprovedeno je na Insititutu za nutriciju u Beču istraživanje 
efekta 300 g povrća odnosno 25ml biljnog ulja na metabolizam i parametre 
oksidativnog stresa kod dijabetičara drugog tipa. Intervencija je izvršena u toku 
osam nedelja u kojoj je prisustvovalo 99 osoba, od kojih su 76 (35 IDDM i 41 
NIDDM) imale dijabetes, 12 su imale povišen šecer u krvi i 11 koje su bile 
zdravi. Svi učesnici istraživanja su bili obučavani o zdravoj ishrani na 
informacionim večerima. Na četri sastanka učesnicima je vadjena krv. Prvo 
uzimanje krvi je održano prije intervencije studije (T_0), drugo nakon četiri 
nedelje (T_1) i treće nakon osam sedmica(T_2) nakon intervencije. Poslednji 
uzorak krvi uzet je posle šesnaest sedmica (osam sedmica nakon završetka 
studije). 
Koncentracija MDA porasla je minimalno tokom istraživanja u sve četiri grupe. 
Međutim ovo je bio pozitivan razvoj, jer zbog velike potrošnje biljnih ulja je MDA 
mogao čak veći da bude od dobijene vrijednosti.  
Mogući razlog za ovakav rezlutat možda leži u pozitivnom efektu 
polinezasićenih masnih kiselina biljnih ulja ili zbog relativno visoke dnevne 
potrošnje povrća. 
Antioksidativni kapacitet, koji se uz FRAP i ORAC metode ispitivao, može kroz 
četiri sedmice intervencione studije značajno da bude povišen. Vrijednosti nisu 
bile značajno povišene kroz još naredne četiri sedmice intervencije. Mogući 
razlozi za značajno povećanje antioksidativnog kapaciteta  
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u plazmi pacijenata dijabetesa tipa 2 bili bi relativno velika potrošnja povrca 
(bogati sa antioksidantima) kao i potrošnja ulja (bogata su sa polinezasićenim 
masnim kiselinama). 
Za kraj može se potvrditi da dnevno konzumiranje povrća i biljnih ulja povećava 
antioksidativni kapacitet plazme kod dijabetičara drugog tipa kao i da ne mijenja 
signifikantno MDA koncentraciju.  
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